****

**Copyright Information of the Article Published Online**

|  |  |
| --- | --- |
| **TITLE** | Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future |
| **AUTHOR(s)** | Jean Klastersky, Marianne Paesmans, Michel Aoun, Aspasia Georgala, Angela Loizidou, Yassine Lalami, Lissandra Dal Lago |
| CITATION | Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L. Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future. *World J Clin Infect Dis* 2016; 6(3): 37-60 |
| URL | http://www.wjgnet.com/2220-3176/full/v6/i3/37.htm |
| DOI | http://dx.doi.org/10.5495/wjcid.v6.i3.37 |
| OPEN ACCESS | This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| CORE TIP | The overall presentation of febrile neutropenia has considerably changed over the last 50 years. Pre­vention is now feasible with the use of granulocyte colony stimulating factors. If fever appears in a neutro­penic patient, empirical therapy with broad spectrum antibiotics is mandatory; it should be adapted to the risk of severe complications that can be now predicted in individual patients using a reliable scoring system. Special situations such as persisting fever in neutropenic patients, the risk of invasive fungal infection and the management of older patients are crucial questions that are discussed as well as the issues linked to the high cost of prophylaxis and therapy. |
| KEY WORDS | Fever; Neutropenia; Prophylaxis; Algorithm; Cancer |
| COPYRIGHT | © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| NAME OF JOURNAL | World Journal of Clinical Infectious Diseases |
| ISSN | 2220-3176 (online) |
| PUBLISHER | Baishideng Publishing Group Inc, 8226 Regency Drive, Pleasanton, CA 94588, USA |
| WEBSITE | http://www.wjgnet.com |

REVIEW

Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future

Jean Klastersky, Marianne Paesmans, Michel Aoun, Aspasia Georgala, Angela Loizidou, Yassine Lalami, Lissandra Dal Lago

Jean Klastersky, Marianne Paesmans, Michel Aoun, Aspasia Georgala, Angela Loizidou, Yassine Lalami, Lissandra Dal Lago,Institut Jules Bordet, Service de Médecine, Centre des Tu­meurs de l’Université Libre de Bruxelles, 1000 Brussels, Belgium

Author contributions: Klastersky J contributed to historical background and introduction; Paesmans M contributed to risk prediction for complications and death; Klastersky J contributed to prevention according to risk; Aoun M contributed to empiric therapy according to risk; Georgala A contributed to emergence of resistant strains; Loizidou A contributed to persisting febrile neutropenia; Lalami Y contributed to cost issues; Dal Lago L contributed to febrile neutropenia at the extreme of age; Klastersky J and Aoun M contributed to conclusion.

Correspondence to:Jean Klastersky, MD, PhD, Institut Jules Bordet, Service de Médecine, Centre des Tumeurs de l’Université Libre de Bruxelles, 1, rue Héger-Bordet, 1000 Brussels, Belgium. jean.klastersky@bordet.be

Telephone:+32-2-5417396 Fax:+32-2-5380858

Received:June 30, 2015 Revised:April 25, 2016 Accepted:June 1, 2016

Published online: August 25, 2016

**Abstract**

Febrile neutropenia (FN) is responsible for significant morbidity and mortality. It can also be the reason for delaying or changing potentially effective treatments and generates substantial costs. It has been recognized for more than 50 years that empirical administration of broad spectrum antibiotics to patients with FN was associated with much improved outcomes; that has become a paradigm of management. Increase in the incidence of microorganisms resistant to many antibiotics represents a challenge for the empirical antimicrobial treatment and is a reason why antibiotics should not be used for the prevention of neutropenia. Prevention of neutropenia is best performed with the use of granulocyte colony-stimulating factors (G-CSFs). Prophylactic administration of G-CSFs significantly reduces the risk of developing FN and consequently the complications linked to that condition; moreover, the administration of G-CSF is associated with few complications, most of which are not severe. The most common reason for not using G-CSF as a prophylaxis of FN is the relatively high cost. If FN occurs, in spite of prophylaxis, empirical therapy with broad spectrum antibiotics is mandatory. However it should be adjusted to the risk of complications as established by reliable predictive instruments such as the Multinational Association for Supportive Care in Cancer. Patients predicted at a low level of risk of serious complications, can generally be treated with orally admini­stered antibiotics and as out-patients. Patients with a high risk of complications should be hospitalized and treated intravenously. A short period of time between the onset of FN and beginning of empirical therapy is crucial in those patients. Persisting fever in spite of antimicrobial therapy in neutropenic patients requires a special dia­gnostic attention, since invasive fungal infection is a possible cause for it and might require the use of empirical antifungal therapy.

**Key words:** Fever; Neutropenia; Prophylaxis; Algorithm; Cancer

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L. Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future. *World J Clin Infect Dis* 2016; 6(3): 37-60 Available from: URL: http://www.wjgnet.com/2220-3176/full/v6/i3/37.htm DOI: http://dx.doi.org/10.5495/wjcid.v6.i3.37

**Core tip:** The overall presentation of febrile neutropenia has considerably changed over the last 50 years. Pre­vention is now feasible with the use of granulocyte colony stimulating factors. If fever appears in a neutro­penic patient, empirical therapy with broad spectrum antibiotics is mandatory; it should be adapted to the risk of severe complications that can be now predicted in individual patients using a reliable scoring system. Special situations such as persisting fever in neutropenic patients, the risk of invasive fungal infection and the management of older patients are crucial questions that are discussed as well as the issues linked to the high cost of prophylaxis and therapy.

**HISTORICAL BACKGROUND AND INTRODUCTION**

In 1966, Bennett *et al*[1] showed convincingly that severe and/or protected neutropenia, in cancer patients, was associated with increased risks of severe infection. At that time, patients receiving chemotherapy (CT) were almost exclusively those with acute leukemia, a condition associated with severe bone marrow dysfunction. As a result of severe neutropenia, overwhelming infection-mainly caused by Gram-negative sepsis - was responsible for a mortality in the range of 90%, often precluding the completion of successful anti-leukemic therapy[2]. It was also observed at that time that mortality resulting from sepsis, in those severely neutropenic patients, was early after the onset of fever and that fever was often the only manifestation of the infection; this led to the concept of febrile neutropenia (FN), which was widely accepted as a significant clinical syndrome.

Today, the syndrome has become more hetero­geneous; most patients with FN are receiving relatively less myelotoxic CT for solid tumors; as a consequence, the overall incidence of FN in CT-treated patients has dropped to 10% and the overall mortality, in cases of Gram-negative bacteremia, is about 20%[3]. At the same time, there has been a significant shift in the micro­biological etiology of FN in neutropenic patients; gradually Gram-positive infections became more prevalent and, actually, Gram-positive and Gram-negative microorganisms are involved, as a cause of bacteremia in patients with FN, in 50% of the cases, respectively[3].

A major advance in the approach of FN has been the introduction of empirical broad spectrum antimicrobial therapy as soon as fever appeared in a neutropenic patient[4]. That concept that has never been challenged in a comparative trial, was then against the dogma of treating infection; however, it proved to be obviously so effective that it is still accepted as a paradigm for the management of FN today[5].

However, with the changing epidemiology of FN, it became obvious that all patients with FN probably had no longer the same risk of complications and death; this observation led to the search for prognostic factors of these complications and, consequently, with the possibility of prediction of that risk, to adjustments of empirical therapy. These aspects will be dealt with in details later in this paper. Finally, a major issue in CT treated cancer patients is the prevention of FN; these aspects will also be discussed in detail later.

**NATURAL HISTORY OF FN**

The severity of neutropenia - which directly influences the frequency of FN - is clearly related to the intensity of CT (number of agents and respective doses, as well as the myelotoxic potential of each component). However, the relationship between the type of CT and the risk of FN is far from being perfect. There are models that classify the common CT regimens according to the risk of FN as being low (< 10%), intermediate (10%-20%) or high (> 20%)[6,7] but their predictive values are far from being optimal because they do not take into account the factors linked to the patients and to the underlying disease(s) (cancer and co-morbidities) which can increase the risk of developing FN and result in different frequencies of FN with the use of the same type of CT. These factors, which also increase the risk of complications and death during an episode of FN, will be discussed later.

It has been shown, in patients with many different tumors (lymphoma, breast, colon, lung, ovary and others) that the risk of developing FN is maximal during the first cycle of CT and diminished afterwards[8]. While the precise reason for that is not known, the clinical implica­tion is very clear: If a prophylaxis of FN exists (this will be discussed later), it should be applied from the first cycle of CT.

As shown in Table 1, FN is associated with a signi­ficant frequency of severe complications and deaths. These data are derived from a study of 2142 patients with FN registered in two observational studies conducted in different institutions and different countries[3]. It is shown that the type of underlying neoplasia, be it hema­tological malignancy or solid tumor, does not influence significantly the incidence of complications or deaths during episodes of FN; on the other hand, the presence of bacteremia significantly increases both morbidity and mortality. Unfortunately, bacteremia is not easy to predict on a clinical basis at the time of onset fever, although manifestations such as high fever, hypotension and thrombocytopenia are possible clues for it. It is also important to stress that the presence of a focal infection (*e.g.*, pneumonia or cellulitis) increases the risk of dying during an episode of FN; these focal in­fections are probably a surrogate for bacteremia but they also can lead to specific local complications by themselves[9]. Besides the severity of neutropenia (which is mainly influenced by the type of CT administrated) and the presence of bacteremia (which is difficult to predict) other factors influence significantly the risk of complications and death during an episode of FN. Among these factors, age (> 65 years) plays a critical role[10]. As shown recently, adverse events (including neutropenia) were more frequent in elderly patients[11]; the importance of prevention of severe neutropenia in elderly patients cannot be overemphasized.

Besides age and the other predisposing factors to complications and death, various comorbidities such as the stage of the neoplastic disease, poor nutrition, diabetes, chronic pulmonary disease, renal function impairment, and many others increase the morbidity and mortality of FN. Although the precise evaluation of the risk of FN associated with these various comorbidities, is not always easy to define, it is clear that it significantly increases with the number of comorbidities that are present in a patient[8,12].

Before finishing this introductory review of the past and present of FN, it is important to stress two important consequences of the development of FN in a patient. The first is the possible impact of FN on the following courses of CT as in some patients the dose of CT may be reduced or its timing modified, with possible reduction of the dose intensity, jeopardizing the efficacy of anticancer treatment; this might be particularly detrimental for patients treated with curative intent or in the adjuvant or neoadjuvant setting.

The second aspect to be stressed is that the cost of FN is substantial; it is estimated to be in the range of $16000 for each episode, with those episodes associated with complications or death being the most expensive[13]. Although these cost figures vary from country to country and from institution to institution, it is generally con­sidered that they are underestimated, especially if all the expenses, including namely the social costs, are taken into account.

**RISK PREDICTION FOR COMPLICATIONS AND DEATH**

***Past achievements***

FN is a limiting factor for CT administration and requires prompt initiation of antimicrobial treatment. It is a pos­sibly lethal complication with a mortality rate as high as 10% and associated costs are important especially if patients need to be hospitalized[14]. On the other hand, FN has long been recognized as a heterogeneous syndrome in terms of type and site of infection, further neutropenia duration, *etc*. Some patients at high risk may therefore be undertreated at the time of initiation of empiric treatment and some patients may be over­treated. Risk prediction is therefore an important issue with therapeutic implications: If correctly identified, low-risk patients may benefit from simplified therapy (oral therapy, outpatient treatment) and high-risk patients might benefit from more aggressive initial antimicrobial therapy and/or from early intensive care.

At least, two approaches can be considered to pre­dict risk: One is to make use of clinical criteria defined alone without assessment of the possible interactions between them, the other is to integrate independent risk factors to produce a model predicting risk. Risk models have the following advantages: They only make use of the non-redundant information, they should produce objective and reproducible prediction, they have known characteristics. They however have drawbacks: They need to be validated, updated and tested in different settings. Nevertheless, we will focus our report on risk models only and for populations of adult patients.

When risk models are to be developed, an outcome has first to be defined: It might be development of bac­teremia, development of invasive bacterial infection, response to empiric treatment, serious medical complica­tion, death or death due to infection. This last endpoint is likely the most relevant one but due to its low fre­quency, developing a model for its occurrence is highly challenging due to sample size issues. The validated models have made use of a composite endpoint: Occur­rence of a serious medical complication and/or death. Secondly, the clinical use for the model needs to be defined in order to optimize the model for the chosen goal.

***Models developed to predict low-risk of serious medical complications and/or death***

There are essentially two models that have been vali­dated.

**Talcott’s model:** The first one was developed and validated by Talcott *et al*[15]: It was derived, using clinical judgment, on a series of 261 febrile neutropenic episodes and firstly validated on a series of 444 episodes. Unfortu­nately, that model, although being reliable for predicting FN patients at low risk of complications (with an excellent positive predictive value but lacking from sensitivity), was not effective[16], as 9 patients out of 30 (30%) needed readmission. After that pilot study, a randomized clinical trial was initiated comparing management of patients with FN in-hospital or with early discharge. Planned sample size was 448 patients for showing an increase from 4% to 10% of the complication rate although an equivalence design (or a non-inferiority of the experi­mental arm) would have been more convincing. The trial was closed for poor accrual after recruitment of 113 patients (66 in the in-hospital arm and 47 in the arm with early discharge). Complication rates were 9% *vs* 8%. Surprisingly, there was no evidence for improvement of patients’ quality of life (QoL) in the experimental arm but costs were reduced with the home arm[17].

**Multinational Association for Supportive Care in Cancer model:** The Multinational Association for Supportive Care in Cancer (MASCC) risk-index score has been developed (Table 2) and its clinical prediction rule for identification of low-risk patients was first validated in the primary publication[18]. The event “occurrence of a serious medical complication” was precisely defined in the study protocol and can be found in[18]. The MASCC score has been, since 2002, accepted as a standard technique to predict low-risk of complications in patients with FN by the European Society of Medical Oncology[19] and by Infectious Diseases Society of America (IDSA)[20,21]. Indeed, several validation studies[22-28] were published and already tabulated in a review published in supportive care in cancer (Table 3)[29]. From this review, it should be stressed that the performance of the MASCC model decreases when haematological patients are present in the patients populations. The positive predictive value is > 90% when the score is used for patients with solid tumor but may decrease to 83% when haematological patients are eligible.

The MASCC model represents an improvement over the Talcott’s classification[18]. The selected factors appear to be more specifically associated with the clinical seve­rity of the FN episode rather than with the underlying cancer. A weakness of the model is that it includes a subjective assessment, burden of illness but all the attempts to substitute it with more objective factors failed. Hematological malignancy was not included in the final model. Neutropenia duration certainly plays a role too but cannot be reliably assessed at the onset of the febrile episode. The MASCC score is however not perfect, especially in patients with hematological patients. However, up to now, attempts to improve it did not lead to the development of validated models ready to use in clinical practice[30-32].

The use of the MASCC model to guide the mana­gement of a febrile neutropenic episode has been studied and includes the choice of the empiric regimen (intravenous, oral, monotherapy or combination) or the setting of treatment (in-hospital, in-hospital with early discharge or ambulatory) according to risk[33]. For instance, oral therapy has been shown to be safe in patients predicted at low-risk by the MASCC score[24,25,34-37] as well as a management including early discharge, expected to improve patients QoL, to reduce risk of nosocomial infections and costs, individual[24,38] studies as well as in meta-analyses[39,40]. Even, in hematological patients, outpatient treatment seems to be possible in patients who are clinically stable and defervesced[23]. It should be stressed however that low-risk prediction is not the only criterion for suitability for oral and/or ambulatory therapy as other factors need to be considered (like social factors and acceptance of home therapy by patients and their physicians).

***Models developed to predict low-risk of serious medical complications and/or death***

**MASCC model:** The MASCC model was developed to predict a low risk of serious complications and the threshold of 21 was chosen to optimize sensitivity for a targeted positive predictive value. However, the value of the score estimates the probability of complications and other thresholds could be considered when prediction of high-risk is the goal as the threshold of 21 is clearly associated to a too low sensitivity. Combining the data from 2 observational studies[41], overall complications rate was 79% and mortality rate was 36% in patients with a score < 15. However, no clinical prediction rule for predicting high-risk was proposed. Blot and Nitenberg[42] suggested to improve the performance of the MASCC score for high-risk prediction by repeating calculation of the severity score and by including number of organ dysfunction but they didn’t propose any practical model. Some laboratory parameters have been suggested to be associated with poor outcome in patients with FN as thrombocytopenia and increased CRP[43], serum lactate[44,45], electrolytes abnormalities[46].

**CISNE score:** A Spanish team worked on the prediction of serious complications for patients with FN. In a first study, designed as a case-control study[28], they reviewed retrospectively 861 episodes of FN and matched patients who developed complications to patients who did not (3 controls for 1 case): They suggested that ECOG per­formance status ≥ 2, chronic obstructive pulmonary disease, chronic heart failure, stomatitis grade ≥ 2, monocyte count and stress hyperglycemia are factors associated to complications. From a subsequent data set of 1133 patients with FN and clinically stable 3 h after FN diagnosis, they derived, using logistic regression analysis, and validated a score predicting complications, ranging from 0 to 8 (Table 4)[47]. They defined low (score of 0) and intermediate risk (score of 1 or 2) *vs* high-risk (score > 2). The characteristics of CISNE score and MASCC score (at the threshold of 21 chosen however to predict low-risk) for predicting high-risk are shown in Table 5. Although the overall misclassification rate is lower for MASCC than for CISNE, sensitivity for predicting high-risk is much better for CISNE score as well as negative predictive value. Positive predictive value is poor for both systems. The authors acknowledged the fact that a threshold of 21 for MASCC was not intended to predict high-risk but stated that CISNE score remains more performant at other thresholds than the MASCC score.

***Perspectives***

Many achievements were reached for predicting low-risk for FN and allowed to successfully adapt therapeutic strategy. There is however place for improvement, especially for increasing the positive predictive value overall and certainly for patients with hematological malignancies. Further research may include further inves­tigation of laboratory parameters, investigation genetic predisposition for infection development or monitoring of intermediate-risk patients with early repeated measure­ments of risk scores of whom we don’t know the value. The situation is more challenging for identifying patients at high-risk. The CISNE score was only very recently proposed and its usefulness for improving patients outcome remains to be demonstrated. Clinical trials should be conducted to assess the value of “aggressive” empiric therapy or the use of early intensive care. Due to the relative low frequency of complications, further achievements in this area will be possible only thanks to large international collaboration studies that should be strongly encouraged.

**PREVENTION OF FN**

As has been stated in the introduction, FN is associated with serious medical complications; moreover, it can jeopardize the effectiveness of CT and represents signi­ficant extra-cost. Although, the incidence of FN and the frequency of associated complications have decreased significantly over the last 50 years, FN remains a major medical problem in patients receiving CT, especially in view of the large numbers of patients receiving CT today all over the world. It is estimated that 10% of these patients will develop FN and that 10% of them will die as a result of it; which means that eventually 1% of the patients receiving CT die as a consequence of neutropenia, a figure which is appalling for patients treated with a curative intent or in the adju­vant or neoa­djuvant setting[1].

The first attempts to prevent FN in CT-treated patients has been done with antimicrobials (first non-absorbable antibiotics and later, co-trimoxazole) with some success, but also with the observation of the emer­gence of resistant strains that limited soon or later the efficacy of that approach[2,3].

Recently, fluoroquinolones have been broadly used for that prophylaxis. Once again, most studies showed that fluoroquinolones reduced the incidence of infection and the infection-related mortality in neutropenic patients but at the expense of emergence of quinolone-resistant strains[4]. This should at the end make the prophylaxis useless; moreover, these strains jeopardize the use of fluoroquinolones as a therapy of FN, in low risk patients, as will be discussed elsewhere. For all those reasons, the use of antimicrobials, including fluoroquinolones, should be discouraged. Guidelines from American Society for Clinical Oncology limit the use of antibacterial prophyl­axis to patients at high risk for FN; others recommend avoidance of such practices for the prevention of FN[5].

The use of granulocyte-colony stimulating factors (G-CSF)[1]; this approach is highly effective, without virtually any short-term side effects; on the other hand, more problematic is the cost of such a prophylaxis and this is clearly a limiting factor for a large scale use today. Two pivotal studies have established the effectiveness of primary prophylaxis with either filgrastim[6] or pegfil­grastim[1]. Pegfilgrastim differs from filgrastim by its prolonged time of action, as the polyethylene glycol tail added to the filgrastim molecule, prevents it from being excreted through the kidneys; the elimination of pegfilgrastim depends only on its inactivation by the rising numbers of neutrophils. Therefore, pegfilgrastim can be administered as a single injection after CT, whereas filgrastim requires daily injections and periodic granulo­cyte level monitoring until neutrophil recovery (usually 7 to 10 doses). This makes pegfilgrastim use easier for the patient and the physician, but an injection of peg­filgrastim costs at least twice as much as a full course (10 administrations) of filgrastim.

Several meta-analyses have confirmed the efficacy of G-CSF for the prevention of FN in CT-treated patients, and have shown that mortality associated with FN could be reduced[8,9].

Is pegfilgrastim more effective than filgrastim in pre­venting FN? A recent meta-analysis suggests that it might be the case[10]. However, outside clinical trials, it appears that in the community oncology practice, despite that filgrastim is often given later and for shorter times than officially recommended, no major differences are seen between the efficacy of pegfilgrastim and filgrastim[11,12].

The current recommendations, namely those pro­posed by European Organization for Research and Therapy of Cancer (EORTC)[13] state that patients with a > 20% risk of developing FN should receive G-CSF primary prophylaxis and those with a risk < 10% should not. Patients with an intermediary risk (10%-20%) should be evaluated for further risk factors, such as age > 65 years, advanced disease and various comorbidities (as discussed previously in the introductory section); if present, those factors should lead to a more liberal use of G-CSF in that group of patients. The general use of algorithm in the use of G-CSF in neutropenic patients for primary prophylaxis of FN is indicated in Figure 1.

The official recommendation to pay attention to age and other comorbidities for deciding to use G-CSF a risk of FN < 20% is an important step towards a better protection of more patients against the adverse consequences of FN. Actually, most of the patients receiving CT today have a < 20% risk of developing FN, as indicated in Figure 2; applying strictly the initial rule allowing primary prophylaxis with G-CSF only in patients with a risk > 20%, would have without protection a substantial number of patients[48]. The introduction of criteria such as age and comorbidities in patients with an intermediary risk, allows to extend the potential benefit of primary prophylaxis to more patients.

A further issue might be the optimal management of patients with a risk < 10%. It has been shown that the efficacy of primary prophylaxis is actually better in patients with a lower risk of developing FN when compared to those with a higher risk[8]. In that context, and in a re­trospective analysis, it has been found that a reduced dose of filgrastim (300 g on day 8 and 12), after a CT carrying a 7% risk of FN in patients with breast cancer, was similarly effective as a full course of filgrastim[49]. Of course, these stimulating observations need confirmatory prospective trials, to see whether it might be appropriate to propose primary prophylaxis with reduced doses, especially if there are other risk factors (*e.g*., age and comorbidities) or if CT is given with a curative intent or in an adjuvant or neo-adjuvant context[50]. In that context, it should be stressed that, under “real life” conditions, there is wide variation in the patterns of G-CSF utiliza­tion by practicing oncologists. A recent study indicates that despite guidelines, the use of G-CSF has not been consistent. Wide variations in overuse, underuse and misuse are very common, which means possibly that physicians might perceive the usefulness of administering G-CSF, even if the guidelines are not strictly followed; alternatively, it might mean that present guidelines do not always fit clinical practice[51].

Cost is the main problem for a possible extension of the use G-CSF for primary prophylaxis of FN[51]; it is difficult to accept, on ethical grounds, that the ad­ministration of a potentially life-saving procedure is based merely on economic conditions. Moreover, the trade-off used in these early - but influential studies - is controversial, as it was based mainly on the cost for hos­pitalization for FN, which is definitely not the only aspect of the cost of an episode of FN. For all those reasons, the balance between the cost and the benefits of primary prophylaxis with G-CSF of FN needs to be reevaluated[50,52].

A potential solution to the limiting effect of cost on the more liberal use of G-CSF might come from the introduction of biosimilars to filgrastim or pegfilgrastim[53]. Several of such preparations have been approved in Europe and are proposed at lower prices than the original products. Thus, a combination of modified schedule of administration, tailoring the dose to the clinical needs, and a price reduction might make G-CSF prophylaxis for FN available to more patients. Once again, it should be emphasized that new paradigms need to be based on adequately conducted clinical trials.

**EMPIRIC THERAPY ACCORDING TO RISK**

The elements of the management of FN have been a matter of intense research, improvement and refinement over the years (Table 6).

In the late 80’s, there was a general perception that all neutropenic patients do not have the same risk of developing life-threatening complications. Not all neutropenic patients need hospitalization and intrave­nous antibiotics until resolution. Talcott *et al*[54] reported the first work that tried to assess the risk of adverse outcome during a neutropenia. However, the Talcott’s criteria lack sensitivity (30%) and in the early 2000’s, the MASCC developed an index scoring system that allows the selection of low-risk patients with good sensitivity (80%) and specificity (71%)[18]. The MASCC index has been tested in several independent trials[22,23] and is the most widely used in adult population. Thus progressively, a risk-adapted strategy for the management of FN was implemented.

***Empiric treatment of low-risk patients***

The major objective of identifying low-risk patients is to develop a strategy of management that decreases the costs, improves the QoL while maintaining safety. Over the time, there was an evolution in the different strategies used as well as in the selection criteria of low-risk patients. One of the first strategies consisted in early discharge to continue intravenous antibiotics on an outpatient basis and was tested successfully in two pilot trials[16,55] and in a randomized multicenter study including 80 adults[56]. In the second one, ambulatory intravenous antibiotics were given from the onset of FN. Once-daily dosing regimens such as ceftriaxone alone or combined with aminoglycoside are the most practical. Using such a strategy, a German multicenter study reported a hospital readmission rate of 24% for persisting fever or clinical deterioration[57].

The third one, a step-down strategy from inpati­ent intravenous antibiotics to oral antibiotics with early discharge has the advantage of allowing a period of observation and assessment of microbiology results which is critical for safety. The oral antibiotic therapy selected was a combination of ciprofloxacin and amo­xicillin/clavulanate and was used successfully in two non-randomized trials including low risk patients with hema­tological malig­nancies[23,58]. Finally, giving oral antibiotics from the onset of FN to low-risk patients, with early discharge, is probably the strategy that best meets the objectives of reducing costs and improving QoL[59]. Because of their high oral bioavailability, good tolerance and bactericidal activity particularly against GNB[60], fluoroquinolones either alone or in combination with anti-Gram-positive agents such as clindamycin[61] or amoxicillin/clavulanate[62], have been the mainstay oral therapy. A first step was to establish the safety of an oral regimen given from onset of FN. This has been accomplished through the achievement of two randomized trials com­paring ciprofloxacin plus amoxycillin/clavulanate with either ceftazidime[63] or ceftriaxone plus amikacin[64], in an inpatient setting. More recently, once daily oral moxi­floxacin 400 mg monotherapy has been shown to be equivalent to the standard[38]. Concern has been raised about the limited activity of moxifloxacin against Pseudomonas aeruginosa (*P. aeruginosa)*. However, the frequency of this organism in the population of solid tumors or lymphoma at low risk FN is very uncommon and should be assessed locally. In this trial XV of the EORTC, 59% of patients could be discharged early with only 5% readmission rate for clinical deterioration and other medical complications.

Several studies have assessed the role of oral anti­biotics given from onset of FN with immediate discharge without hospitalization for observation[60,65-68]. All excluded patients with acute leukemia and hematopoietic stem cell transplantation. Patients should be able to ingest and tolerate oral antibiotics with the first dose being tested at the emergency room. A close follow-up is undertaken with phone calls and a visit every other day until resolu­tion. Figure 3 summarizes some of the elements that may help in the management of patients with FN at low risk.

Despite the increasing resistance of Gram-negative bacteria to fluoroquinolones over time, their efficacy in empiric oral therapy for low-risk patients does not seem to be affected. On one hand, the rate of failure because of fluoroquinolone resistance is not higher in the recent trials as compared to older ones and on the other hand, the incidence of GNB bacteremia is low. However, epide­miological variations between institutions may exist and a careful monitoring is recommended.

***Empiric treatment of high-risk patients with FN***

Inpatient management with parenteral broad-spectrum antibiotics is the standard care of FN patients at high-risk. A -lactam agent active against GNB including *P. aeruginosa* remains the central core of empiric therapy. However, the increasing resistance of GNB over the years has made the -lactam choice much more chall­enging[69]. There are many geographical differences in the epidemiology of microbial resistance and it is more likely that the local epidemiology than any global data, for the selection of initial for empiric therapy[70]. Until the 90’s, this choice was mainly influenced by one risk which was *P. aeruginosa* resistance to the different -lactams.

Nowadays, this choice depends on too many risks. The risk of ESBL producing GNB especially *K. pneumoniae* and *E. coli*, risk of a MDR non-fermenter such as *P. aeruginosa*, *Acinetobacter baumanii* or *S. maltophilia*, risk of carbapenemase producing pathogen in addition to the risk of MRSA, VRE and anaerobes (see epidemio­logical section). Any delay in the early adequate therapy is associated with an increased mortality[71,72]. Therefore, defining risk factors for MDR pathogens, in neutropenic patients, is determinant for empiric antibiotic selection and outcome. The risk factors for MDR pathogens identified include prior exposure to broad-spectrum antibiotics, the severity of underlying disease such as in acute myelocytic leukemia, and the presence of medical comorbidities, as well as the presence of urinary catheter[73]. However, these are quite common to allow a specific selection of the patients who ultimately develop an infection due to MDR pathogens. ESBL-GNB or VRE stool colonization was associated with subsequent bacteremia due to the same pathogen in a prospective study[74] in hematological malignancy patients, with a RR of 4.5 for ESBL-GNB (95%CI: 2.89-7.04) and a RR of 10.2 for VRE (95%CI: 7.87-13.32).

Thus, surveillance cultures should be reassessed and validated prospectively for both infection control purposes and selection of -lactam empiric therapy. Patients who are not at risk of ESBL-GNB infection will receive therapy with piperacillin/tazobactam or cefepime or ceftazidime, while patients at risk of ESBL-GNB, will receive upfront a carbapenem[74]. Anti-anaerobic coverage is indicated for necrotizing gingivitis, typhlitis and peri-anal abscess[19,75]; piperacillin/tazobactam and carbapenems are, however, active against the majority of anaerobe[76]. In case of allergy to penicillin, aztreonam combined with a glyco­peptide is an acceptable alternative.

A combination therapy with an aminoglycoside has no advantage and is more toxic than monotherapy[77,78]. However, for the subgroup of patients with signs of sepsis or septic shock, the mortality is unacceptably high, especially when empiric therapy proves to be inade­quate[79]. In such conditions, a combination with an aminoglycoside for a limited duration up to 3 d, seems reasonable[80,81].

In institutions where MDR non-fermenters such as *P. aeruginosa* or *Acinetobacter baumanii* or *carbapenemase*-producers enterobacteriae are endemic, combination with colistin has been advocated[82]. Empiric addition of a glycopeptide didn’t show benefit in reducing treatment failure, in gram-positive infections[83]. However, addition of empiric glycopeptide under certain circumstances, is indicated such as in patients already colonized by MRSA, if MRSA is endemic in the institution, in the presence of folliculitis, furonculosis or catheter-related cellulitis and if viridans group *Streptococci* penicillin-resistance is prevalent[75].

In allogeneic hematopoietic stem cell transplant patients (HSCT) colonization by vancomycin-resistant enterococci (VRE) and T-cell depletion are important risk factors for VRE bacteremia[84]. In such patients, early empiric combination with linezolid or high-dose dapto­mycin (> 6 mg/kg per day) is justified[85,86]. Figure 4 provides indications for the selection of empiric therapy in high-risk patients with GN.

**EMERGENCE OF RESISTANT STRAINS**

The discovery and clinical use of antibiotics was officially initiated in 1936 with sulfonamides and followed in the 1940s with penicillin and streptomycin; a whole new era of anti-infective drugs was inaugurated with successful treatment of previous lethal diseases. The dream started fraying when the first resistant strains against sulfona­mides[87], penicillin[88-90] and streptomycin appeared[90].

The exhilaration accompanying the modern antibiotics was over by the early 2000s; antimicrobial resistance emerged as part of the adaptive mechanisms deployed by micro-organisms (bacteria, fungi, viruses and parasites) in order to survive in a stressful environment (inside and outside the hospital). Bacteria developed successful resistance strategies through the last 6 decades. On the other hand, microbiologists and clinicians faced the ESKAPE concept: *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterobacteriaceae*[91] and new comers such as *Mycobacterium tuberculosis*, HIV, *Aspergillus* *sp*. and malaria; very few antimicrobials were active against these bugs and the new drugs were even less designed, developed or available for human use.

In the narrow field of FN, complicating aggressive CT regimens, prophylaxis by oral antibiotics[92], broad-spectrum early antibiotherapy[75] and optimal supportive treatment[13] are well-established attitudes in order to decrease mortality and morbidity due to FN. These atti­tudes have to be revised and adapted in order to face the ESKAPE bugs and to continue to use antimicrobials to treat severe infections jeopardizing the prognosis of potentially curable malignant diseases.

The resistance related to antibiotics is a natural phenomenon associated to the evolution of bacterial life and the genes of resistance are frequently issued from essential genes. Evidence exists that these genes pre-existed the era of antibiotics and they probably developed in antibiotic producing bacteria[93,94]. Bacteria, especially those of commensal and environmental flora use the mechanisms of resistance in order to survive in nature[95,96]. Antibiotics create a strong selective pressure on bacteria and create favorable conditions for the development of resistance; resistance to antibiotics is the final product of a complex process including multiple genetic maneuvers.

These genetic maneuvers include 3 levels. The first level is the point mutations (micro-evolutionary change) that occur in in a nucleotide base pair; the point mutations will create alterations in enzyme substrate specificity or the target site of an antibiotic, interfering with its activity. The second level of genomic variability (macro-evolutionary change) in bacteria results in massive modi­fications (inversions, duplications, insertions, deletions, or transpositions) of large portions of DNA as a single event. Specialized genetic elements called integrons, transposons, or insertion sequences generate these massive rearrangements independently from the rest of bacterial genome[95]. The third level of genetic variability is due to the acquisition of foreign DNA carried by plas­mids, bacteriophages, isolated sequences of DNA and transposable genetic elements from other bacteria. The further inheritance of foreign DNA will contribute to enhance genetic variability of bacteria and increase their capacity to respond to selection pressures such as the use of antimicrobials[93].

Bacteria develop antibiotic resistance through (at least) eight different mechanisms: Enzymatic alteration (-lactamases, extended-spectrum -lactamases, car­bapenemases), decreased permeability (outer/inner membrane permeability), efflux, alteration of the target site, protection of the target sight, overproduction of the target, bypass of the inhibited process and bind-up of the antibiotic. All classes of antibiotics may be affected *via* different mechanisms. The use of old (polymyxins, metronidazole) and new (linezolid, tigecycline) antibiotics when antibacterial resistance became important led to the apparition of resistant strains against these drugs, *via* the same mechanisms deployed against traditional anti­biotics. Additionally to these mechanisms, bacteria may associate different mechanisms of antibiotic resistance resulting to MDR (multiple drug resistance)/Pan-resistance strains. In 2005, Deplano *et al*[97] described a Belgian out-break of Pan-resistant *Pseudomonas aeruginosa* (89% of the isolates belonged to serotype O:11). The Pan-resistance was due to the overexpression of AmpC chromosomal -lactamases conferring resistance to multiple -lactam antibiotics associated to the mutational loss of OrpD porin, conferring resistance to imipenem and the upregulation of the MexXY efflux system which exports fluoroquinolones, tetracycline, aminoglycosides and antipseudomonal -lactam molecules[97]. Metho­dical transfer of multiple-resistance elements located on mobile genetic elements (transposons, plasmids) can help bacteria to acquire MDR/Pan-resistance[98,99]. The capacity of bacteria to seize numerous antibiotic resistance genes is illustrated by resistance integrons, which can insert resistance gene cassettes into their *attΙ* integration site and are often found on transposons carried on plasmids, with obviously endless recombinant capacity[100].

Moving in the inner circle of the ESKAPE bugs and their impact on the management of FN is strewn with pitfalls. Understanding the various mechanisms leading to resistance and being acquainted with the established epidemiological profiles will permit the quick and right choice of (empirical) antibiotic treatment in the advent of fever during neutropenia.

The *Enterococcus faecium* is actual the most impor­tant pathogen (among the *Enterococcus* sp.) in hospital acquired infections, followed by the *Enterococcus faecalis*. Enterococci are less virulent than other Gram-positive cocci and usually occur in the context of polymicrobial infection in debilitated patients. The acquisition of resis­tance (to multiple antibiotics including vancomycin; VRE) allowed the emergence of superinfections in immunocompromised patients[101]. Acute outbreaks are usually monoclonal[101] and the hands of health workers spread Enterococci among patients. Patients may be colonized with *E. faecium* on the gastrointestinal tract and thus serve as a reservoir; adequate identification and management of these patients are the only way to prevent transmission to other patients and subsequent outbreaks[102]. Resistant strains to vancomycin (and to teicoplanin) appear when the production of peptidoglycan precursors is modified and therefor present a weak affinity for glycopeptides; Van A and VaB are the most frequent phenotypes associated to glycopeptide resistance[103]. Admission to intensive care and length of hospitalization, prior use of broad spectrum antibiotics, severity of illness and exposure to other patients colonized with VRE are well known factors for developing colonization/infection to VRE. Linezolid and daptomycin constitute the main therapeutic issues, but controlled trials lack actually[104].

The *Staphylococcus aureus* is well-known to be re­sistant to natural penicillins since the mid 40’s; resis­tance to methicillin (a penicillinase-resistant penicillin) was first described in the mid 60’s while the resistance to vanco­mycin was first reported in the mid-90’s (Figure 1). The *mec* A gene, as part of the mobile genetic element named staphylococcal cassette chromosome is responsible for the synthesis of the penicillin-binding protein, PBP2a, located in the bacterial membrane and being able to catalyze the transpeptidation reactions of peptidoglycan during cell wall construction; it’s an inducible protein and under the effect of regulatory genes implicated to its transcription (*mec R1*, *mecΙ,* *blaZ*, BlaR1 and BlaΙ), resistance towards -lactams is observed[105,106]. The -lactamases genes (*bla*Z, *BlaR1* and *Bla*) can produce hydrolyzing enzymes targeting the -lactam ring[106]. Broad use of vancomycin provoked the emergence of intermediate (VISA)/resistant (VRSA) strains[107,108]. The mechanism of resistance in VISA is related to a thickening of the wall cell containing dipeptides that trap vancomycin and thus decrease the amount of drug directed against intracellular targets[109]. The mecha­nism of resistance in VRSA is related to a plasmid transfer containing the *van*A gene from Enterococci to *Staphy­lococcus aureus*[110]. While precise guidelines about treat­ment of MRSA infections exist[111], treatment against VISA/VRSA is mainly based on experimental trials using daptomycin, quinupristin-dalfopristin and linezolid[112,113].

The *Klebsiella pneumonia* and the *Enterobacteriaceae* represent the major providers of extended-spectrum -lactamases (ESBLs) and carbapenemases. ESBLs include enzymes that have derived from narrow spec­trum -lactamases (TEM-1, TEM-2, SHV-1) or from chromo­somally encoded -lactamases produced by *Kluyvera* *sp*. (CTX-M type ESBLs)[114]. The broad use of carbapenems for serious infections due to ESBLs-producing bacteria selected the carbapenemases (mainly OXA-48, KPC, VIM, NDM); these plasmid-acquired enzymes hydrolyze most -lactams including cabapenems. Their spread all over the world is spectacular[115,116] and worry about the outcome of serious infections due to these germs is more than real as therapeutic armamentarium is reduced to colistin, aminoglycosides and tigecycline. The detection of carbapenemases should be triggered when the *Entero­bacteriaceae* have resistance or reduced susce­ptibility to carbapenems[117], while screening (stool, anal swabs) should be performed during outbreaks and endemic scenarios[116]. Mortality is mainly evaluated among blood-stream infections: It may vary from 39% to 53% but remains unacceptably high[74,118,119]. Well-identified risk factors (in multivariate analysis models) are the age of patient, APACHE Ⅱ (Ⅲ) score at infection onset, inap­propriate antimicrobial therapy, onset of bacteremia while in the intensive care unit and malignancy; combination of antibiotics were more efficient than monotherapy and the emergence of strains resistant to colistin is already described[74,118-120].

The *Acinetobacter baumanii* and the *Pseudomonas aeruginosa* are the most popular and the most implicated in serious infections within immunocompromised patients between non-fermentative Gram-negative bacilli. Broad-spectrum empiric antibiotics always include coverage against Pseudomonas aeruginosa, in the setting of FN[75], while Acinetobacter baumanii is related to serious infec­tions in the intensive care unit (ICU)[121]. *Pseudomonas aeruginosa* may acquire genes encoding a tremendous amount of -Lactamases such as the OXA and PSE type -Lactamases, KPC and the metallo--Lactamases. The metallo--Lactamases can induce resistance to all -Lactam antibiotics (including carbapenems and ex­cepting aztreonam) and the -Lactamase inhibitors are inefficient; worst, the genes coding for theses enzymes may be linked to genes inducing resistance to other anti-pseudomonas drugs[122]. Nonetheless the most common mechanism of resistance to carbapenems is the loss of an outer-membrane protein called OrpD, following a mutation[123]. Other mechanisms such as upregulation of efflux pumps, outer-membrane impermeability, enzy­matic alterations of the antibiotics and the 16S ribosomal RNA methylation may lead resistance to all class of anti-pseudomonas drugs including aminoglycosides[122-124]. The *Acinetobacter baumanii* infections occur more often in the ICU and the burn units and neutropenic patients seem to avoid reasonably this pathogen[69]. Besides intri­nsic resistance (cephalosporinase: *bla* ADC, (OXA-69), *Acinetobacter baumanii* may acquire genes encoding different -lactamases/carbapenemases; these enzymes are OXA-type -lactamases (OXA-23) and metallo--lactamases (IMP, VIM, GIM, SPM)[125]. Fluoroquinolones are neutralized when point mutations in the in the quinolone resistance determining region of DNA gyrase gene occur[126] and upregulated efflux pumps may contribute to fluoroquinolone resistance. Ami­noglycoside resistance results when enzymes capable of modyfing aminoglycosides are produced: Aph A6 3’-aminoglycoside phosphotransferase type Ⅵ will inac­tivate amikacin[126] and adenyltransferases (aadA1, aadB) or acetyltranferases (aacC1, aacC2) will neutralize gentamycin and tobramycin[126,127]. Unfortunately, upre­gulated efflux pumps of the AdeABC type induced resis­tance to tigecycline[128].

Despite fascinating progress in treating serious bac­terial diseases performed in the last century and since the discovery of penicillin, the emergence of resistant strains is the major threat in the 21st century. Frail patients undergoing sophisticated treatments (transplantations, CT, immunotherapy) for complex diseases such as cancer, autoimmune conditions are exposed to a supplementary risk of complications due to non-treatable bacterial in­fections[129,130].

The economic impact of infections due to resistant bacteria is well-known: The length of hospitalization is longer, the hospital charges are higher and the mortality/morbidity are increased[131,132]. The infection control team and the antimicrobial stewardship programs seem to be the most promising tools in fighting against resistant strains in the lack of new antibacterials; implementation of strategies preserving antibacterials may is the future in modern medicine if we don’t want to lose the progress achieved in the past decades. Management of FN needs to be carefully thought in the advent of these disturbing elements and close collaboration with specialized teams in controlling infectious diseases is the only way to bring through the ESKAPE pathogens[98].

**PERSISTING FN**

***Definition***

Persistent febrile neutropenia (PFN) is FN that does not resolve in spite of the empirical administration of broad-spectrum antibacterial agents. It can concern 30%-40% of the patients presenting FN. The diagnosis of PFN requires at least 5 d of therapy in patients with haematological malignancy, including HSCT[133-135] but only 2 d in solid tumours[75,136], probably due to different immune response. Patients with haematological malignancies are usually more seriously ill, than patients with solid cancers[137].

***Etiology of PFN***

The most frequent cause of fever in high risk neutropenic patients unresponsive to broad spectrum antimicrobials is fungal infection (45%), followed by bacterial, viral infections, toxoplasmosis, drugs, toxic effects of CT and antitumor response (Table 7)[137].

***Diagnostic approach***

PFN for more than 3 d should prompt a thorough search for a source of infection. PFN with neutropenia lasting more than 7 d in high-risk hematological patients should lead to an evaluation for invasive fungal infection with a chest CT scan looking after pulmonary nodules or nodular pulmonary infiltrates and early assessment with bronchoscopy, bronchoalveolar lavage with cultures/stains, a sinus CT scan[75] and a regular *Aspergillus* galac­tomannan antigen testing and/or -D-glucan detection. Repeated imaging may be required in patients with persistent pyrexia.

Procalcitonin (PCT) monitoring can be useful, a delayed PCT peak higher than 500 mg/mL suggest the early diagnosis of invasive fungal disease and PCT decrease reflects response to antifungal therapy[138].

Diarrhea, if present, should be assessed by analyzing a stool sample for *C. difficile* toxin. An abdominal CT may be helpful for the diagnosis of neutropenic entero­colitis[139]. Surveillance of IV catheters for possible skin bloodstream breakthrough infection is also indicated[75].

An evaluation for viral infections, by herpesviridae (Herpes, Varicella Zoster, HHV6, HHV8), Cytomegalovirus, Epstein Barr, but also respiratory virus, as guided by the local epidemiology (respiratory syncytial virus, influenza, parainfluenza) is recommended especially in high risk hematological patients. Eventually, exclusion of other non-infectious sources of recurrent or persistent fever like drugs, thrombophlebitis, cancer, resorption of hematoma is warranted[75].

Prospective trials are presently ongoing to evaluate the utility and cost-effectiveness of PET/CT in identifying sites of infection in cancer patients with PFN without an obvious source, in order to improve targeted therapy.

***Therapeutic attitude***

Modifications to the initial empirical antibiotic regimen should be guided[75] firstly by possible changes of the clinical stability, without a source of infection detected; in hemodynamically stableand asymptomatic patients, watchful waiting and re-evaluation for new possible infection is indicated, while in hemodynamically unstable patients, the antimicrobial regimen should be broadened to target drug-resistant bacteria. Delaying appropriate antibiotic therapy for such pathogens, is associated with increased mortality[140].

Unusual infections should be considered, particularly in the context of a rising C-reactive protein (CRP), in such cases proceeding to imaging of chest and abdomen is advisable. Sometimes the investigations may be directed by clinical findings[4,141].

***Therapeutic approach for fungal infections***

Empiric antifungal therapy should be considered in high-risk neutropenic patients who PFN after four to seven days and without identified source for the fever[75]. The incidence of fungal infection (especially *Candida* or *Aspergillus* *sp.*) rises after patients have experienced more than 7 d of PFN. In 1970s, already several studies have shown that invasive fungal infections were a common cause of PFN (9%-37.5%)[142-146] and was associated with significant mortality (69%)[145].

The IDSA guidelines recommend lipid formulation of amphotericin B, caspofungin, voriconazole, or itraco­nazole as suitable options for empiric antifungal therapy in PFN. The choice of the initial antifungal agent may vary based on epidemiology and local susceptibility patterns[133], toxicity and the cost of the antifungals.

Resolution of fever occurs in approximately 40%-50% of patients given empirical antifungal therapy[143,144,147,148], but such a successful outcome does not prove that the patient had indeed an occult fungal infection, since slow responses to empiric antibacterial therapy can occur.

Fluconazole can be given as first-line treatment provided that the patient is at low risk of invasive as­pergillosis, has not received an azole antifungal as pro­phylaxis and local epidemiological data suggest low rates of azole-resistant *Candida*[19].

Liposomal amphotericin B or an echinocandin anti­fungal such as caspofungin are appropriate first-line treatments in high risk patients with PNF without an obvious site of infection and also in patients already ex­posed to an azole or known to be colonized with non-albicans *Candida*[19].

Addition of the newer antifungal agents active against possible azole-resistant *Candida sp*. Is also recom­mended, if the patient has been already treated with fluconazole prophylaxis.

In patients with nodular pulmonary infiltrates, invasive mold infection should be strongly suspected and prompt assessment with bronchoscopy, bronchoalveolar lavage for cultures and galactomannan testing should be per­formed; in those patients a preemptive treatment with voriconazole or a lipid formulation of amphotericin Bis indicated.

PFN receiving anti-mold prophylaxis should be treated with a different class of antifungal than the one used for prophylaxis, in order to avoid cross resistance. The usual sensitivity and resistance of the common fungi are indicated in Table 8[149-151].

Pre-emptive antifungal therapy implies a diagnostic workup with chest and/or sinus computed tomography, serum galactomannan and/or -D-glucan to evaluate fungal infections in patients with PFN[133]; that approach has been proposed in order to reduce unnecessary use of empirical antifungal therapy, associated toxicity and high cost[147]. Patients receiving pre-emptive antifungals are more likely to present a documented invasive fungal infection (IFI) compared to patients receiving empirical therapy by the time the antifungal agent is started[152].

Paediatric population with PFNare also at high risk for IFI. Prospective monitoring of serum galactomannan twice per week in high-risk hospitalized children for early diagnosis of invasive aspergillosis is probably indicated.

Computed tomography (CT) of the lungs and tar­geted imaging of other clinically suspected areas of infection, as well as other investigations, such as BAL and *trans*-bronchial or *trans*-thoracic biopsy are indicated in the case of pulmonary lesions[153]. CT of the sinuses is proposed in children of at least 2 years, although imaging during prolonged FN can be inconclusive and symptoms of sinonasal IFD in children are scarce[154,155].

***Particular entities of PFN***

Recurrent or recrudescent fever refers to a new episode of fever after an initial resolution of fever with antimicrobial therapy when the patient remains neutropenic[155]. This is relatively common, but it has not been adequately studied. Bacterial and fungal infections are common causes of this syndrome (around 30%)[156,157]. The various guidelines do not separate recurrent/recrudescent fever from per­sistent fever, although these two may be clinically and etiologically different.

Engraftment fever (myeloid reconstitution syndrome) consists of a new onset or worsening of inflammatory and/or infectious process, in temporal relationship to neutrophil recovery after aplasia[157,158]. This has to be differentiated from superinfection or the immune recon­stitution syndrome. The engraftment syndrome is a diagnosis of exclusion, which presents particularly in the setting of stem cell transplantation (autologous or allogeneic) consisting in fever, rash and pulmonary infil­trates originally and is usually treated with corti­costeroids when severe.

**ECONOMIC AND COST ISSUES RELATED TO FN**

***General considerations and perspectives for clinical practice***

Treatment of FN usually requires several days of hospitalization, diagnostic procedures, administration of intra­venous empiric broad-spectrum antibiotics and hematopoietic growth factors[159,160]. Thus, such medical manage­ment is resource intensive. It is not surprising that FN has a considerable economic impact, particularly in the inpatient setting[51,161].

Our understanding of such a problematic issue is mainly derived from several seminal United States re­trospective economic analyses, highlighting average costs per hospitalization for FN management, ranging from $18880 to $22086 (€15000-€24000). The direct costs for outpatient management were considerably lower, at $985 per episode. Patients with hematological malignancies usually have much higher hospitalization costs associated with each episode than those with solid tumors ($US23000-38600 *vs* $US7598-14900)[162-165]. In a recent review, a large variation in estimation among the cost of illness studies in lymphoma patients experiencing FN have been reported, ranging from $5819 to $34756 (2013 $) per episode of FN[166]. It seems now well estab­lished that such previous exclusive estimations, based on hospitalization, may have underestimated costs by as much as 40% by ignoring important costs occurring after hospital discharge[167].

Similar trends with a different cost burden degree were observed in western European developed countries, with smaller studies providing estimates of the average charge for FN-related hospitalization ranging from €2619 in Spain to €4931 in France[168,169]. In a recent study con­ducted in Ireland, the mean cost per FN episode in the inpatient setting was estimated to be €8915[170]. It should be noted that results of cost-effectiveness studies may differ greatly across different countries and health care systems. Future cost evaluation studies should compare the cost of FN and intervention costs within the same health care system, and not between countries, so as to determine more accurately if the intervention is cost-effective.

Furthermore, results of studies that were conducted may not be directly applicable to other settings. More­over, literature data based on clinical trials may carry the risk of representing care in overselected populations rather than “real life” practice. Many potential factors account for the large variation in estimating the cost of FN, such as the year of pricing, the perspective employed, and the cost estimation approach used. The public health care system is unique for each country, with different standards of care as well as different costing of health care resources.

Since FN is an acute condition, and typically produces temporary complete disability, the cost involved from the patient time lost from work was initially thought to be non-significant[171]. Thereafter, such indirect costs, including costs associated with patient work loss, care­giver work loss, paid caregiver and/or non-revenue-generating support centers, were estimated with great variations between studies, ranging from 11% to 44% of the total cost of FN management[161,166,172]. Future studies should place greater emphasis on improving the accuracy of providing a clearer description of these indirect costs.

The major economic impact of neutropenic compli­cations is mainly related to the cost of hospitalization and the associated length of stay (LOS). In a retrospective analysis, it has been demonstrated that one-third of patients hospitalized for more than 10 d account for 78% of the total cost. The average LOS decreased over time by 10% while the cost per day increased by 28%, raising the total cost per episode of FN by 13%. The mean LOS was longer for patients with leukemia (19.0 d) compared to patients with lymphoma and solid tumors[51]. A recent publication on subpopulations of FN admissions with breast cancer in the United States between 2009 and 2011, showed, despite a shorter LOS than previously reported (5.7 d *vs* 8.0 d, *P* < 0.05), a significantly higher mean hospital charge ($ 37087)[173] than prior observation from former observations from Kuderer and colleagues ($ 12372)[8], suggesting that FN related hospi­talizations continue to account for highly significant care expenditure.

Low risk patients generally have short hospitaliza­tions and account for a relatively small proportion of the overall costs associated with FN[174]. There is also strong evidence suggesting that costs of in-hospital treat­ment are greater than the costs of ambulatory care for FN[166,175]. Therefore, strategies that support FN outpatient treatment may have important clinical and economic impacts[16,18,61]. However, these patients may have been selected for outpatient treatment because of their lower risk for complications. Future prediction risk models should not only include risk factors of FN to be considered for use of prophylactic therapies but also the predictors of higher cost of FN as well. Currently, the MASCC scoring system is widely used to prognosticate the severity of FN among cancer patients[18]. However, there is room to improve the sensitivity and specificity of the prognostic model. Considered that the management strategies of low-risk and high-risk FN are different, improving the current prognostic model to predict the severity of FN is worth to further explore in future studies.

Undoubtedly, recombinant G-CSFs represent a major clinical achievement[8]. Meta-analyses, which have shown that pegfilgrastim performs as well as or better than filgrastim in reducing FN rates for patients undergoing CT[176]. Consistently, several studies evaluated the relative cost effectiveness of pegfilgrastim, and showed that any incremental costs are justifiable given the clinical outcomes[177-180].

As already said, it is possible that these economic considerations have been the main incentive for in­ternational guidelines, justifying the use of primary prophylaxis, at a risk level > 20%[13,181,182]. However, considering only the cost of hospitalization for setting such threshold may not be optimal. Such guidelines do not consider all aspects of value in cancer patients, namely clinical impacts on QoL and mostly, potential effect of completing full dose CT therapeutic plan, with subsequent disease control and impact on survival, especially in the curative setting.

Both filgrastim and pegfilgrastim are expensive ($2600 and $3500 respectively for full treatment per cycle), and their economic burden is inseparable from the economics of FN. These agents will allow a greater relative dose intensity, less dose-delays and thereby, greater costs associated with the use of CT agents. Their high cost should be balanced not only against the cost of FN but also to the impact on increased clinical outcomes, such as QoL and survival. However, the exact economic benefits of such FN prophylaxis are not completely understood and established, mainly due to the lack of consistency in general use of G-CSFs among physicians. Indeed, under- and over-prophylaxis with G-CSFs re­main a reality, being the consequences of either a bad knowledge and clinical applications of the guidelines, or the willingness for clinicians to overprotect their patients undergoing CT. It has been suggested that G-CSFs are underused for CT regimens with high risk of FN, and overused for those associated with low risk[183].

Actually, the risk of development of FN is not always easily determined on the basis of the type and dose of CT, and still many patients with a risk < 20% still develop FN, with a rate of complications similar to that of patients with a high risk[184]. Moreover, it seems that efficacy of G-CSF prophylaxis might be better in populations with low risk of FN (≤ 10%)[8]. Current guidelines will have to be revisited to allow a larger number of patients to have access to primary prophylaxis, without compromising cost efficacy. Hence, other prophylaxis strategies have been explored, including in particular, limitation of pri­mary prophylaxis to the first two cycles of CT only[185] or shorter duration of G-CSF primary prophylaxis (2 *vs* 7 daily injections)[49], but with reports of conflicting and ambiguous results in the literature. Further studies are needed and will be performed in this specific topic.

The great majority of previous large FN trials consi­dered hematological malignancies, lymphomas, breast and lung cancers. Other groups, such head and neck cancer patients, may deserve special attention, because they truly represent a high risk group in terms of age, co-morbidities and aggressiveness of multimodal thera­pies. In this group, platinum and taxane-containing regi­mens (*i.e.*, induction TPF) have a reported FN incidence ranging from 5.2%-20%[186,187] and therefore, they are not considered as high risk to have access to primary prophylaxis with G-CSFs. It is now established and recognized that patients considered for clinical trials (with shorter therapy durations) are usually well selected (usually excluding high risk such elderly patients), and could be different from those unselected and managed in real-life daily clinical practice among the community setting.

A recent retrospective analysis from a Japanese group reported a 41%, 25% and 33% incidence of FN in the first, second and third cycles of taxane and platinum-based CT regimens. G-CSF was used in 58 out of 71 patients (82%) during the first cycle, but exclusively therapeutically and not prophylactically following health insurance rules for G-CSFs in Japan[188]. Their relative dose intensity was around 80% of other reports. Tube feeding, diabetes mellitus and presence of CT-related gastrointestinal adverse effects (such mucositis, diarrhea and emesis) were significant predictors of FN. In this analysis, 62% and 70% of the patients had received prior CT and radiation respectively. The major interest of this retrospective analysis, and despite several limitations, is to show the much higher risk of FN in community setting than in clinical trials in a very specific group of tumors with high needs. Further investigations are needed for a better management and prophylaxis of FN in head and neck cancer patients.

Finally, a more comprehensive consideration of value should encompass not only the cost, but also potential survival benefit, QoL and equity between patients. More affordable G-CSFs, QoL through the use of biosimilars, might influence our prescribing to prevent FN in the future[189,190]. Several studies have demonstrated that the biosimilar G-CSF is equivalent in terms of efficacy and safety when compared against native G-CSF[191-193]. Although we dispose of encouraging clinical and safety outcomes, there is still a need for longer follow-up studies to confirm the safety, efficacy as well as cost effective­ness of these biosimilars.

**FN AT THE EXTREME OF AGE (DAL LAGO L)**

***Elderly population***

Due to the ageing, European population aged 65 years and older is projected to increase, leading to even older patients with cancer[194].

There is a paucity of evidence-based data for cancer management in older patients because of the under­representation in studies. Indeed, many clinical trials have tended to exclude older individuals, either on the basis of age alone, comorbidity, or both[195]. Consequently data about anti-cancer treatments are extrapolated from results in younger population, with a risk of over­treatment and/or complications such as FN following CT. Indeed, many clinical trials have tended to exclude older individuals, either on the basis of age alone, comorbidity, or both. The explanation for this situation is complex and associated with a biased approach by both physicians[196]. However, we do know that older patients are just as likely as younger ones to participate in clinical trials if given the opportunity.

***Older age as risk factor for FN***

Particular consideration should be given to the high risk of FN in elderly patients (aged 65 and over). Primary prophylaxis of FN is currently indicated for a risk > 20% of FN, but FN is more often complicated in older patients, even if the theoretical risk of FN is < 20%[13].

In a phase Ⅲ randomized trial in 509 metastatic breast cancer patients who received first-line CT with doxorubicin or a pegylated liposomal formulation. One of the risk factors for FN was advanced age[197].

***FN prophylaxis***

Elderly cancer patients cannot tolerate standard doses of CT but should probably benefit more from prophylaxis because of the frequency and severity of myelo­sup­pressive complications.

One of the first randomized studies that demon­strated the benefit of primary prophylaxis of FN during CT evaluated the incidence of FN and related events in 852 older cancer patients (≥ 65 years of age) with either solid tumors or non-Hodgkin’s lymphoma receiving peg­filgrastim; the administration of pegfilgrastim resulted in a significantly lower incidence of FN for both solid tumor and NHL patients compared with reactive use[198].

Cooper *et al*[9] meta-analysis of GCS-F for FN pro­phylaxis following CT demonstrated that there was no clear difference in GCS-F effectiveness in studies restricting to elderly population. Indeed, Lyman *et al*[51] meta-analysis of 59 individual randomized controlled trials involving nearly 25000 patients with solid tumors or lymphoma demonstrated significant reductions in all-cause mortality over the period of 2 years follow-up with GCS-F-supported CT (RR = 0.93), independent of the age group[17].

In a phase Ⅲ randomized trial of 175 NSCLC patients randomly assigned to CT with or without addition of G-CSF to antibiotic prophylaxis, it was shown a decreased in­cidence of FN with the addition of G-CSF, and older age was related to the risk of FN in cycle 1[199].

Phase Ⅲ results of 779 patients with ovarian cancer treated with carboplatin or cisplatin/paclitaxel were re­trospectively analyzed according to feasibility, toxicity, and QoL in patients aged < 70 or ≥ 70 years; 13% of patients were aged ≥ 70 years. Toxicities were com­parable between elderly and younger patients, except for FN (5% *vs* < 1%, *P* = 0.005)[200].

***FN complications***

It is therefore important to identify patients at risk for complications if FN appears using instruments like the MASCC score). This score identifies age 65 or older as an important risk factor for disease burden in case of FN[18].

***Perspectives***

Risk factors of CT toxicity (for example FN) other than chronological age should be identified and evaluated, as that chronologic age is often different from physiologic age. The next step in geriatric oncology will be to imple­ment ongoing predictive models for CT toxicity that integrate patient age, and characteristics of the tumor and its treatment as well as laboratory values and overall geriatric assessment[201,202]. This might allow to better selection of patients who will benefit of primary GCS-F prophylaxis of FN.

**CONCLUSION**

During the past 50 years, FN prognosis has dramatically changed as a result of better supportive care in patients with cancer and namely the use of empirical broad spectrum anti-microbial therapy. Nonetheless, FN is still diagnosed in 10% of the CT-treated patients and is re­sponsible overall for a 10% mortality without taking into account the morbidity resulting from FN and the possible negative effect on cancer therapy.

A major advance in the management of FN has been the stratification of the population of patients with FN for the risk of complications and death. Using validated reliable predictive instruments, such as the MASCC score, it is possible to identify a population of “low risk” patients who can benefit from simplified and less expensive therapeutic approaches (*e.g*., orally administered anti­microbial therapy and early home return).

Although the MASCC scoring index has been widely accepted, there is still room for improving its effec­tiveness, especially in some subset of the FN population, namely in patients with hematological malig­nancies. Similarly, attempts to improve the performance of the score by adding to it, some biological parameters are promising. Although the MASCC score can identify patients at high risk of complications during FN, more precise prediction of such patients is needed, to make possible earlier and closer monitoring of those patients who present still a high rate of death and complications, mainly because of uncontrolled sepsis. New paradigms for the diagnosis and management of non-low-risk patients with FN are urgently needed.

A major advance in the management of FN has been the introduction of the GCSFs, which efficacy for the prevention of CT-associated has been demonstrated beyond any doubt: 50%-80% of such episodes can now be avoided. Unfortunately GCSFs are expensive and this has led to restrictive algorithms for their use, to balance the cost of the prophylaxis and that of the management of FN; these considerations usually do not take into account the effect of FN on the well-being (QoL) of the patients. It is highly desirable that future research focuses on the definition of subset of patients who could benefit from GCSF prophylaxis, taking into account not only the type of CT used, but also many comorbid conditions making FN more common and more debilitating.

**REFERENCES**

1 **Bennett CL**, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. *N Engl J Med* 2013; **368**: 1131-1139 [PMID: 23514290 DOI: 10.1056/NEJMct1210890]

2 **Klastersky J**, Debusscher L, Weerts D, Daneau D. Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains. *Pathol Biol* (Paris) 1974; **22**: 5-12 [PMID: 4360753]

3 **EORTC International Antimicrobial Therapy Project Group**. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group. *J Infect Dis* 1984; **150**: 372-379 [PMID: 6384377 DOI: 10.1093/infdis/150.3.372]

4 **Gafter-Gvili A**, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. *J Antimicrob Chemother* 2007; **59**: 5-22 [PMID: 17077101 DOI: 10.1093/jac/dkl425]

5 **Klastersky J**, Georgala A. Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria. *Crit Rev Oncol Hematol* 2014; **92**: 268-278 [PMID: 25151213 DOI: 10.1016/j.critrevonc.2014.06.002]

6 **Crawford J**, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. *N Engl J Med* 1991; **325**: 164-170 [PMID: 1711156 DOI: 10.1056/NEJM199107183250305]

7 **Vogel CL**, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. *J Clin Oncol* 2005; **23**: 1178-1184 [PMID: 15718314 DOI: 10.1200/JCO.2005.09.102]

8 **Kuderer NM**, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. *J Clin Oncol* 2007; **25**: 3158-3167 [PMID: 17634496 DOI: 10.1200/JCO.2006.08.8823]

9 **Cooper KL**, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. *BMC Cancer* 2011; **11**: 404 [PMID: 21943360 DOI: 10.1186/1471-2407-11-404]

10 **Naeim A**, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). *BMC Cancer* 2013; **13**: 11 [PMID: 23298389 DOI: 10.1186/1471-2407-13-11]

11 **Morrison VA**, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. *J Manag Care Pharm* 2007; **13**: 337-348 [PMID: 17506600 DOI: 10.18553/jmcp.2007.13.4.337]

12 **Weycker D**, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. *Clin Ther* 2009; **31**: 1069-1081 [PMID: 19539108 DOI: 10.1016/j.clinthera.2009.05.019]

13 **Aapro MS**, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. *Eur J Cancer* 2011; **47**: 8-32 [PMID: 21095116 DOI: 10.1016/j.ejca.2010.10.013]

14 **Kuderer NM**, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. *Cancer* 2006; **106**: 2258-2266 [PMID: 16575919 DOI: 10.1002/cncr.21847]

15 **Talcott JA**, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. *J Clin Oncol* 1992; **10**: 316-322 [PMID: 1732432]

16 **Talcott JA**, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. *J Clin Oncol* 1994; **12**: 107-114 [PMID: 8270967]

17 **Talcott JA**, Yeap BY, Clark JA, Siegel RD, Loggers ET, Lu C, Godley PA. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. *J Clin Oncol* 2011; **29**: 3977-3983 [PMID: 21931024 DOI: 10.1200/JCO.2011.35.0884]

18 **Klastersky J**, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J Clin Oncol* 2000; **18**: 3038-3051 [PMID: 10944139]

19 **de Naurois J**, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann Oncol* 2010; **21** Suppl 5: v252-v256 [PMID: 20555092 DOI: 10.1093/annonc/mdq196]

20 **Hughes WT**, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002; **34**: 730-751 [PMID: 11850858 DOI: 10.1086/339215]

21 **Freifeld AG**, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. *Clin Infect Dis* 2011; **52**: e56-e93 [PMID: 21258094 DOI: 10.1093/cid/cir073]

22 **Uys A**, Rapoport BL, Anderson R. Febrile neutropenia: a pro­spective study to validate the Multinational Association of Sup­portive Care of Cancer (MASCC) risk-index score. *Support Care Cancer* 2004; **12**: 555-560 [PMID: 15197637 DOI: 10.1007/s00520- 004-0614-5]

23 **Cherif H**, Johansson E, Björkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. *Haematologica* 2006; **91**: 215-222 [PMID: 16461306]

24 **Klastersky J**, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. *J Clin Oncol* 2006; **24**: 4129-4134 [PMID: 16943529 DOI: 10.1200/JCO.2005.03.9909]

25 **Innes H**, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lym­phomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. *Support Care Cancer* 2008; **16**: 485-491 [PMID: 17899215 DOI: 10.1007/s00520-007-0334-8]

26 **Baskaran ND**, Gan GG, Adeeba K. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. *Ann Hematol* 2008; **87**: 563-569 [PMID: 18437382 DOI: 10.1007/s00277-008-0487-7]

27 **Hui EP**, Leung LK, Poon TC, Mo F, Chan VT, Ma AT, Poon A, Hui EK, Mak SS, Lai M, Lei KI, Ma BB, Mok TS, Yeo W, Zee BC, Chan AT. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. *Support Care Cancer* 2011; **19**: 1625-1635 [PMID: 20820815 DOI: 10.1007/s00520-010-0993-8]

28 **Carmona-Bayonas A**, Gómez J, González-Billalabeitia E, Canteras M, Navarrete A, Gonzálvez ML, Vicente V, Ayala de la Peña F. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. *Br J Cancer* 2011; **105**: 612-617 [PMID: 21811253 DOI: 10.1038/bjc.2011.284]

29 **Klastersky J**, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. *Support Care Cancer* 2013; **21**: 1487-1495 [PMID: 23443617 DOI: 10.1007/s00520-013-1758-y]

30 **Lalami Y**, Paesmans M, Muanza F, Barette M, Plehiers B, Dubreucq L, Georgala A, Klastersky J. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. *Ann Oncol* 2006; **17**: 507-514 [PMID: 16322116 DOI: 10.1093/annonc/mdj092]

31 **Phillips RS**, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. *BMC Med* 2012; **10**: 6 [PMID: 22257704 DOI: 10.1186/1741-7015-10-6]

32 **Paesmans M**, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Ameye L. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? *Support Care Cancer* 2011; **19**: 1001-1008 [PMID: 20596732 DOI: 10.1007/s00520-010-0925-7]

33 **Kridel R**, Van Delden C, Calandra T, Marchetti O. [Empirical antibiotic therapy for febrile neutropenia]. *Rev Med Suisse* 2008; **4**: 914, 916-919 [PMID: 18578432]

34 **Mebis J**, Goossens H, Berneman ZN. Antibiotic management of febrile neutropenia: current developments and future directions. *J Chemother* 2010; **22**: 5-12 [PMID: 20227985 DOI: 10.1179/joc.2010.22.1.5]

35 **Even C**, Taillade L, Spano JP, Vignot S. [Febrile neutropenia in adult patients with solid tumours: a review of literature toward a rational and optimal management]. *Bull Cancer* 2010; **97**: 547-557 [PMID: 20176547 DOI: 10.1684/bdc.2010.1045]

36 **Tam CS**, O’Reilly M, Andresen D, Lingaratnam S, Kelly A, Burbury K, Turnidge J, Slavin MA, Worth LJ, Dawson L, Thursky KA. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. *Intern Med J* 2011; **41**: 90-101 [PMID: 21272173 DOI: 10.1111/j.1445-5994.2010.02340.x]

37 **Rolston KV**, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. *Support Care Cancer* 2010; **18**: 89-94 [PMID: 19387695 DOI: 10.1007/s00520-009-0634-2]

38 **Kern WV**, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. *J Clin Oncol* 2013; **31**: 1149-1156 [PMID: 23358983 DOI: 10.1200/JCO.2012.45.8109]

39 **Carstensen M**, Sørensen JB. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. *J Support Oncol* 2008; **6**: 199-208 [PMID: 18551855]

40 **Teuffel O**, Ethier MC, Alibhai SM, Beyene J, Sung L. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. *Ann Oncol* 2011; **22**: 2358-2365 [PMID: 21363878 DOI: 10.1093/annonc/mdq745]

41 **Klastersky J**, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. *Int J Antimicrob Agents* 2007; **30** Suppl 1: S51-S59 [PMID: 17689933 DOI: 10.1016/j.ijantimicag.2007.06.012]

42 **Blot F**, Nitenberg G. [High and low-risk febrile neutropenic patients]. *Presse Med* 2004; **33**: 467-473 [PMID: 15105769 DOI: 10.1016/S0755-4982(04)98634-4]

43 **Ahn S**, Lee YS, Chun YH, Kwon IH, Kim W, Lim KS, Kim TW, Lee KH. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. *Support Care Cancer* 2011; **19**: 1151-1158 [PMID: 20552376 DOI: 10.1007/s00520-010-0928-4]

44 **Mato AR**, Luger SM, Heitjan DF, Mikkelsen ME, Olson E, Ujjani C, Jacobs S, Miltiades AN, Shah P, Schuster SJ, Carroll M, Chauffe AD, Fuchs BD. Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hours. *Cancer Biol Ther* 2010; **9**: 585-589 [PMID: 20160493 DOI: 10.4161/cbt.9.8.11270]

45 **Ramzi J**, Mohamed Z, Yosr B, Karima K, Raihane B, Lamia A, Hela BA, Zaher B, Balkis M. Predictive factors of septic shock and mortality in neutropenic patients. *Hematology* 2007; **12**: 543-548 [PMID: 17852435 DOI: 10.1080/10245330701384237]

46 **Shaikh AJ**, Bawany SA, Masood N, Khan AA, Abbasi AN, Niamutullah SN, Zaidi A, Adil S, Kumar S. Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia. *J Cancer* 2011; **2**: 62-66 [PMID: 21326626 DOI: 10.7150/jca.2.62]

47 **Carmona-Bayonas A**, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martínez J, Hernando Cubero J, Espinosa J, Martínez de Castro E, Ghanem I, Beato C, Blasco A, Garrido M, Bonilla Y, Mondéjar R, Arcusa Lanza MÁ, Aragón Manrique I, Manzano A, Sevillano E, Castañón E, Cardona M, Gallardo Martín E, Pérez Armillas Q, Sánchez Lasheras F, Ayala de la Peña F. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. *J Clin Oncol* 2015; **33**: 465-471 [PMID: 25559804 DOI: 10.1200/JCO.2014.57.2347]

48 **Klastersky J**, Paesmans M. Faut-il réévaluer les indications pour l’utilisation des facteurs stimulant la granulopoïèse en fonction des comorbidités présentées par les patients? *Onco Hematol* 2015; In press

49 **Papaldo P**, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, Vici P, Barone C, Ferretti G, Di Cosimo S, Carlini P, Nisticò C, Conti F, Di Lauro L, Botti C, Di Filippo F, Fabi A, Giannarelli D, Calabresi F. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. *J Clin Oncol* 2005; **23**: 6908-6918 [PMID: 16129844 DOI: 10.1200/JCO.2005.03.099]

50 **Klastersky J**, Awada A, Aoun M, Paesmans M. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? *Curr Opin Oncol* 2009; **21**: 297-302 [PMID: 19509500 DOI: 10.1097/CCO. 0b013e32832c9651]

51 **Lyman GH**, Kuderer NM. Epidemiology of febrile neutropenia. *Support Cancer Ther* 2003; **1**: 23-35 [PMID: 18628128 DOI: 10.3816/SCT.2003.n.002]

52 **Klastersky JA**, Paesmans M. Treatment of febrile neutropenia is expensive: prevention is the answer. *Onkologie* 2011; **34**: 226-228 [PMID: 21577026 DOI: 10.1159/000327818]

53 **Ratti M**, Tomasello G. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. *Expert Rev Clin Pharmacol* 2015; **8**: 15-24 [PMID: 25409861 DOI: 10.1586/17512433.2015.984688]

54 **Talcott JA**, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. *Arch Intern Med* 1988; **148**: 2561-2568 [PMID: 3196123 DOI: 10.1001/archinte.1988.00380120031007]

55 **Johansson E**, Björkholm M, Wredling R, Kalin M, Engervall P. Outpatient parenteral antibiotic therapy in patients with haema­tological malignancies. A pilot study of an early discharge strategy. *Support Care Cancer* 2001; **9**: 619-624 [PMID: 11762973 DOI: 10.1007/s005200100247]

56 **Rapoport BL**, Sussmann O, Herrera MV, Schlaeffer F, Otero JC, Pavlovsky S, Iglesias L, Stein G, Charnas R, Heitlinger E, Hand­schin J. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. Standard In-patient care. *Chemotherapy* 1999; **45**: 466-476 [PMID: 10567777 DOI: 10.1159/000007240]

57 **Karthaus M**, Egerer G, Kullmann KH, Ritter J, Jürgens H. Cef­triaxone in the outpatient treatment of cancer patients with fever and neutropenia. *Eur J Clin Microbiol Infect Dis* 1998; **17**: 501-504 [PMID: 9764553 DOI: 10.1007/BF01691133]

58 **Vallejo C**, Caballero MD, García-Sanz R, Hernández JM, Vázquez L, Cañizo MC, Galende J, Colino CI, Gil-Hurlé A, San Miguel JF. Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutro­penic patients. *Hematol Cell Ther* 1997; **39**: 223-227 [PMID: 9395895 DOI: 10.1007/s00282-997-0223-0]

59 **Bolon MK**. The newer fluoroquinolones. *Infect Dis Clin North Am* 2009; **23**: 1027-1051, x [PMID: 19909896 DOI: 10.1016/j.idc. 2009.06.003]

60 **Malik IA**, Khan WA, Aziz Z, Karim M. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. *Clin Infect Dis* 1994; **19**: 522-527 [PMID: 7811873 DOI: 10.1093/clinids/19.3.522]

61 **Rubenstein EB**, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. *Cancer* 1993; **71**: 3640-3646 [PMID: 8490912 DOI: 10.1002/1097-0142(19930601)71:11<3640::AID-CNCR28207 11128>3.0.CO;2-H]

62 **Sipsas NV**, Kosmas C, Ziakas PD, Karabelis A, Vadiaka M, Skopelitis E, Kordossis T, Tsavaris N. Comparison of two oral regimens for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanate. *Scand J Infect Dis* 2007; **39**: 786-791 [PMID: 17701717 DOI: 10.1080/00365540701367769]

63 **Freifeld A**, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. *N Engl J Med* 1999; **341**: 305-311 [PMID: 10423464 DOI: 10.1056/NEJM199907293410501]

64 **Kern WV**, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. *N Engl J Med* 1999; **341**: 312-318 [PMID: 10423465 DOI: 10.1056/NEJM199907293410502]

65 **Papadimitris C**, Dimopoulos MA, Kostis E, Papadimitriou C, Anagnostopoulos A, Alexopoulos G, Papamichael C, Gika D, Mitsibounas D, Stamatelopoulos S. Outpatient treatment of neutro­penic fever with oral antibiotics and granulocyte colony-stimulating factor. *Oncology* 1999; **57**: 127-130 [PMID: 10461059 DOI: 10.1159/000012019]

66 **Chamilos G**, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. *Cancer* 2005; **103**: 2629-2635 [PMID: 15856427 DOI: 10.1002/cncr.21089]

67 **Gardembas-Pain M**, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. *Ann Oncol* 1991; **2**: 485-487 [PMID: 1911455]

68 **Escalante CP**, Weiser MA, Manzullo E, Benjamin R, Rivera E, Lam T, Ho V, Valdres R, Lee EL, Badrina N, Fernandez S, DeJesus Y, Rolston K. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. *Support Care Cancer* 2004; **12**: 657-662 [PMID: 15185134 DOI: 10.1007/s00520- 004-0613-6]

69 **Montassier E**, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: a syste­matic review of epidemiology and antibiotic resistance. *Eur J Clin Microbiol Infect Dis* 2013; **32**: 841-850 [PMID: 23354675 DOI: 10.1007/s10096-013-1819-7]

70 **Mikulska M**, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, Akova M. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. *J Infect* 2014; **68**: 321-331 [PMID: 24370562 DOI: 10.1016/j.jinf.2013.12.006]

71 **Cattaneo C**, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, D’Adda M, Morello E, Re A, Borlenghi E, Manca N, Rossi G. P. aeruginosa bloodstream infections among hematological patients: an old or new question? *Ann Hematol* 2012; **91**: 1299-1304 [PMID: 22349723 DOI: 10.1007/s00277-012-1424-3]

72 **Gudiol C**, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratalà J, Gudiol F. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. *J Antimicrob Chemother* 2010; **65**: 333-341 [PMID: 19959544 DOI: 10.1093/jac/dkp411]

73 **Bodro M**, Sabé N, Tubau F, Lladó L, Baliellas C, Roca J, Cruzado JM, Carratalà J. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. *Transplantation* 2013; **96**: 843-849 [PMID: 23883973 DOI: 10.1097/TP.0b013e3182a049fd]

74 **Tumbarello M**, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carba­penemase-producing K. pneumoniae: importance of com­bination therapy. *Clin Infect Dis* 2012; **55**: 943-950 [PMID: 22752516 DOI: 10.1093/cid/cis588]

75 **Freifeld AG**, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2011; **52**: 427-431 [PMID: 21205990 DOI: 10.1093/cid/ciq147]

76 **Rosa RG**, dos Santos RP, Goldani LZ. Comparison of anti-anaerobic antimicrobial strategies in cancer patients with febrile neutropenia and gastrointestinal symptoms. *BMC Res Notes* 2014; **7**: 614 [PMID: 25196668 DOI: 10.1186/1756-0500-7-614]

77 **Furno P**, Bucaneve G, Del Favero A. Monotherapy or aminogly­coside-containing combinations for empirical antibiotic treat­ment of febrile neutropenic patients: a meta-analysis. *Lancet Infect Dis* 2002; **2**: 231-242 [PMID: 11937423 DOI: 10.1016/S1473- 3099(02)00241-4]

78 **Paul M**, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. *BMJ* 2003; **326**: 1111 [PMID: 12763980 DOI: 10.1136/bmj.326.7399.1111]

79 **Williams MD**, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, Linde-Zwirble W. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. *Crit Care* 2004; **8**: R291-R298 [PMID: 15469571 DOI: 10.1186/cc2893]

80 **Legrand M**, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, Lemiale V, Seguin A, Darmon M, Schlemmer B, Azoulay E. Survival in neutropenic patients with severe sepsis or septic shock. *Crit Care Med* 2012; **40**: 43-49 [PMID: 21926615 DOI: 10.1097/CCM.0b013e31822b50c2]

81 **Cohen J**, Drage S. How I manage haematology patients with septic shock. *Br J Haematol* 2011; **152**: 380-391 [PMID: 21210777 DOI: 10.1111/j.1365-2141.2010.08550.x]

82 **Akova M**, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. *Clin Microbiol Infect* 2012; **18**: 439-448 [PMID: 22507111 DOI: 10.1111/j.1469-0691.2012.03823.x]

83 **Paul M**, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Addi­tional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. *Cochrane Database Syst Rev* 2005; **20**: CD003914 [PMID: 16034915 DOI: 10.1002/14651858.CD003914.pub2]

84 **Kamboj M**, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, Papanicolaou G. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. *Biol Blood Marrow Transplant* 2010; **16**: 1576-1581 [PMID: 20685257 DOI: 10.1016/j.bbmt.2010.05.008]

85 **Smirnova MV**, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA. The antistaphylococcal pharmaco­dynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. *J Chemother* 2011; **23**: 140-144 [PMID: 21742582 DOI: 10.1179/joc.2011.23.3.140]

86 **Rolston KV**, McConnell SA, Brown J, Lamp KC. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. *Clin Adv Hematol Oncol* 2010; **8**: 249-256, 290 [PMID: 20505648]

87 **Kirby WM**, Rantz LA. Quantitative studies of sulfonamide resis­tance. *J Exp Med* 1943; **77**: 29-39 [PMID: 19871262 DOI: 10.1084/jem.77.1.29]

88 **Luria SE**, Arbogast RM. On the relation between penicillin resistance and the production of penicillin inactivators in Staphy­lococcus. *J Bacteriol* 1947; **53**: 253 [PMID: 20341606]

89 **Shwartzman G**. Studies on the nature of resistance of gram-negative bacilli to penicillin; antagonistic and enhancing effects of amino acids. *J Exp Med* 1946; **83**: 65-88 [PMID: 21007276 DOI: 10.1084/jem.83.1.65]

90 **Klein M**. A Mechanism for the Development of Resistance to Streptomycin and Penicillin. *J Bacteriol* 1947; **53**: 463-467 [PMID: 16561295]

91 **Rice LB**. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. *J Infect Dis* 2008; **197**: 1079-1081 [PMID: 18419525 DOI: 10.1086/533452]

92 **Lew MA**, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. *J Clin Oncol* 1995; **13**: 239-250 [PMID: 7799026]

93 **Medeiros AA**. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. *Clin Infect Dis* 1997; **24** Suppl 1: S19-S45 [PMID: 8994778 DOI: 10.1093/clinids/24.Supplement\_1.S19]

94 **Gardner P**, Smith DH, Beer H, Moellering RC. Recovery of resis­tance (R) factors from a drug-free community. *Lancet* 1969; **2**: 774-776 [PMID: 4186024 DOI: 10.1016/S0140-6736(69)90482-6]

95 **Rice WR**, Chippindale AK. Sexual recombination and the power of natural selection. *Science* 2001; **294**: 555-559 [PMID: 11641490 DOI: 10.1126/science.1061380]

96 **Lupski JR**. Molecular mechanisms for transposition of drug-resistance genes and other movable genetic elements. *Rev Infect Dis* 1987; **9**: 357-368 [PMID: 3035697 DOI: 10.1093/clinids/9.2.357]

97 **Deplano A**, Denis O, Poirel L, Hocquet D, Nonhoff C, Byl B, Nordmann P, Vincent JL, Struelens MJ. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. *J Clin Microbiol* 2005; **43**: 1198-1204 [PMID: 15750083 DOI: 10.1128/JCM.43.3.1198-1204.2005]

98 **Rice LB**. Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants. *Antimicrob Agents Chemother* 1998; **42**: 1871-1877 [PMID: 9687377]

99 **Boyd DA**, Tyler S, Christianson S, McGeer A, Muller MP, Willey BM, Bryce E, Gardam M, Nordmann P, Mulvey MR. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. *Antimicrob Agents Chemother* 2004; **48**: 3758-3764 [PMID: 15388431 DOI: 10.1128/AAC.48.10.3758-3764.2004]

100 **Bennett PM**. Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. *Br J Pharmacol* 2008; **153** Suppl 1: S347-S357 [PMID: 18193080 DOI: 10.1038/sj.bjp.0707607]

101 **Vergis EN**, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, Wagener MM, Schmitt B, Muder RR. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. *Ann Intern Med* 2001; **135**: 484-492 [PMID: 11578151 DOI: 10.7326/0003-4819-135-7-200110020-00007]

102 **Byers KE**, Anglim AM, Anneski CJ, Germanson TP, Gold HS, Durbin LJ, Simonton BM, Farr BM. A hospital epidemic of vancomycin-resistant Enterococcus: risk factors and control. *Infect Control Hosp Epidemiol* 2001; **22**: 140-147 [PMID: 11310691 DOI: 10.1086/501880]

103 **Leclercq R**, Courvalin P. Resistance to glycopeptides in enter­ococci. *Clin Infect Dis* 1997; **24**: 545-554; quiz 555-556 [PMID: 9145724 DOI: 10.1093/clind/24.4.545]

104 **Whang DW**, Miller LG, Partain NM, McKinnell JA. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. *Antimicrob Agents Chemother* 2013; **57**: 5013-5018 [PMID: 23896468 DOI: 10.1128/AAC.00714-13]

105 **Deurenberg RH**, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin-resistant Staphylococcus aureus. *Clin Microbiol Infect* 2007; **13**: 222-235 [PMID: 17391376]

106 **Zhang HZ**, Hackbarth CJ, Chansky KM, Chambers HF. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. *Science* 2001; **291**: 1962-1965 [PMID: 11239156 DOI: 10.1126/science.1055144]

107 **Centers for Disease Control and Prevention**. Reduced susce­ptibility of Staphylococcus aureus to vancomycin--Japan, 1996. *MMWR Morb Mortal Wkly Rep* 1997; **46**: 624-626 [PMID: 9218648]

108 **Centers for Disease Control and Prevention**. Staphylococcus aureus resistant to vancomycin--United States, 2002. *MMWR Morb Mortal Wkly Rep* 2002; **51**: 565-567 [PMID: 12139181]

109 **Cui L**, Iwamoto A, Lian JQ, Neoh HM, Maruyama T, Horikawa Y, Hiramatsu K. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. *Antimicrob Agents Chemother* 2006; **50**: 428-438 [PMID: 16436693 DOI: 10.1128/AAC.50.2.428-438.2006]

110 **Courvalin P**. Vancomycin resistance in gram-positive cocci. *Clin Infect Dis* 2006; **42** Suppl 1: S25-S34 [PMID: 16323116 DOI: 10.1086/491711]

111 **Liu C**, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methi­cillin-resistant Staphylococcus aureus infections in adults and children. *Clin Infect Dis* 2011; **52**: e18-e55 [PMID: 21208910 DOI: 10.1093/cid/ciq146]

112 **Cha R**, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. *Antimicrob Agents Chemother* 2003; **47**: 3960-3963 [PMID: 14638509 DOI: 10.1128/AAC.47.12.3960-3963.2003]

113 **Saravolatz LD**, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. *Clin Infect Dis* 2012; **55**: 582-586 [PMID: 22615331 DOI: 10.1093/cid/cis492]

114 **Paterson DL**, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev* 2005; **18**: 657-686 [PMID: 16223952 DOI: 10.1128/CMR.18.4.657-686.2005]

115 **Cantón R**, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N, Nordmann P. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. *Clin Microbiol Infect* 2012; **18**: 413-431 [PMID: 22507109 DOI: 10.1111/j.1469-0691.2012.03821.x]

116 **Munoz-Price LS**, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. *Lancet Infect Dis* 2013; **13**: 785-796 [PMID: 23969216 DOI: 10.1016/S1473-3099(13)70190-7]

117 **Nordmann P**, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V. Identification and screening of carbapenemase-producing Enterobacteriaceae. *Clin Microbiol Infect* 2012; **18**: 432-438 [PMID: 22507110 DOI: 10.1111/j.1469-0691.2012.03815.x]

118 **Zarkotou O**, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. *Clin Microbiol Infect* 2011; **17**: 1798-1803 [PMID: 21595793 DOI: 10.1111/j.1469-0691.2011.03514.x]

119 **Qureshi ZA**, Paterson DL, Peleg AY, Adams-Haduch JM, Shutt KA, Pakstis DL, Sordillo E, Polsky B, Sandkovsky G, Bhussar MK, Doi Y. Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases. *Clin Microbiol Infect* 2012; **18**: 887-893 [PMID: 21951551 DOI: 10.1111/j.1469-0691.2011.03658.x]

120 **Papadimitriou-Olivgeris M**, Marangos M, Christofidou M, Fligou F, Bartzavali C, Panteli ES, Vamvakopoulou S, Filos KS, Anastassiou ED. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. *Scand J Infect Dis* 2014; **46**: 642-648 [PMID: 25017796 DOI: 10.3109/00365548.2014.923106]

121 **García-Garmendia JL**, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Pérez-Paredes C, Barrero-Almodóvar AE, Gili-Miner M. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. *Clin Infect Dis* 2001; **33**: 939-946 [PMID: 11528563 DOI: 10.1086/322584]

122 **Doi Y**, de Oliveira Garcia D, Adams J, Paterson DL. Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. *Antimicrob Agents Chemother* 2007; **51**: 852-856 [PMID: 17158944 DOI: 10.1128/AAC.01345-06]

123 **Livermore DM**. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? *Clin Infect Dis* 2002; **34**: 634-640 [PMID: 11823954 DOI: 10.1086/338782]

124 **Bonomo RA**, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. *Clin Infect Dis* 2006; **43** Suppl 2: S49-S56 [PMID: 16894515 DOI: 10.1086/50447]

125 **Walsh TR**, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? *Clin Microbiol Rev* 2005; **18**: 306-325 [PMID: 15831827 DOI: 10.1128/CMR.18.2.306-325.2005]

126 **Hujer KM**, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, Ecker DJ, Massire C, Eshoo MW, Sampath R, Thomson JM, Rather PN, Craft DW, Fishbain JT, Ewell AJ, Jacobs MR, Paterson DL, Bonomo RA. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. *Antimicrob Agents Chemother* 2006; **50**: 4114-4123 [PMID: 17000742 DOI: 10.1128/AAC.00778-06]

127 **Doi Y**, Wachino J, Yamane K, Shibata N, Yagi T, Shibayama K, Kato H, Arakawa Y. Spread of novel aminoglycoside resistance gene aac(6’)-Iad among Acinetobacter clinical isolates in Japan. *Antimicrob Agents Chemother* 2004; **48**: 2075-2080 [PMID: 15155202 DOI: 10.1128/AAC.48.6.2075-2080.2004]

128 **Ruzin A**, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. *J Antimicrob Chemother* 2007; **59**: 1001-1004 [PMID: 17363424 DOI: 10.1093/jac/dkm058]

129 **Schwaber MJ**, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. *J Antimicrob Chemother* 2007; **60**: 913-920 [PMID: 17848376 DOI: 10.1093/jac/dkm318]

130 **Borer A**, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, Schlaeffer F, Sherf M. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. *Infect Control Hosp Epidemiol* 2009; **30**: 972-976 [PMID: 19712030 DOI: 10.1086/605922]

131 **Lautenbach E**, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. *Clin Infect Dis* 2001; **32**: 1162-1171 [PMID: 11283805 DOI: 10.1086/319757]

132 **Lee SY**, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. *Infect Control Hosp Epidemiol* 2006; **27**: 1226-1232 [PMID: 17080381 DOI: 10.1086/507962]

133 **Bow EJ**, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. *Clin Infect Dis* 2006; **43**: 447-459 [PMID: 16838234 DOI: 10.1086/505393]

134 **Cometta A**, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. *Clin Infect Dis* 2003; **37**: 382-389 [PMID: 12884163 DOI: 10.1086/376637]

135 **Gil L**, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. *Infection* 2007; **35**: 421-427 [PMID: 17926001 DOI: 10.1007/s15010-007-6350-2]

136 **Elting LS**, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EB, Shih YC, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K. Outcomes and cost of outpatient or inpa­tient management of 712 patients with febrile neutropenia. *J Clin Oncol* 2008; **26**: 606-611 [PMID: 18235119 DOI: 10.1200/JCO.2007.13.822]

137 **Corey L**, Boeckh M. Persistent fever in patients with neutropenia. *N Engl J Med* 2002; **346**: 222-224 [PMID: 11807145 DOI: 10.1056/NEJM200201243460402]

138 **Robinson JO**, Lamoth F, Bally F, Knaup M, Calandra T, Marchetti O. Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? *PLoS One* 2011; **6**: e18886 [PMID: 21541027 DOI: 10.1371/journal.pone.0018886]

139 **Cloutier RL**. Neutropenic enterocolitis. *Emerg Med Clin North Am* 2009; **27**: 415-422 [PMID: 19646645 DOI: 10.1016/j.emc. 2009.04.002]

140 **Lodise TP**, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. *Antimicrob Agents Chemother* 2007; **51**: 3510-3515 [PMID: 17646415 DOI: 10.1128/AAC.00338-07]

141 **Averbuch D**, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). *Haematologica* 2013; **98**: 1836-1847 [PMID: 24323984 DOI: 10.3324/haematol.2013.091330]

142 **Stein RS**, Kayser J, Flexner JM. Clinical value of empirical ampho­tericin B in patients with acute myelogenous leukemia. *Cancer* 1982; **50**: 2247-2251 [PMID: 6754059 DOI: 10.1002/1097-0142(19821201)50:11<2247::AID-CNCR2820501102>3.0.CO; 2-7]

143 **Kibbler CC**. Empirical antifungal therapy in febrile neutropenic patients: current status. *Curr Top Med Mycol* 1997; **8**: 5-14 [PMID: 9504062]

144 **Wingard JR**, Leather HL. Empiric antifungal therapy for the neutropenic patient. *Oncology* (Williston Park) 2001; **15**: 351-363; discussion 363-364, 367-369 [PMID: 11301832]

145 **Cho SY**, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. *Am J Clin Pathol* 1979; **72**: 617-621 [PMID: 495566 DOI: 10.1093/ajcp/72.4.617]

146 **Pizzo PA**, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. *Am J Med* 1982; **72**: 101-111 [PMID: 7058815 DOI: 10.1016/0002-9343(82)90594-0]

147 **Segal BH**, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, Wingard JR. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. *Clin Infect Dis* 2007; **44**: 402-409 [PMID: 17205448 DOI: 10.1086/510677]

148 **Klastersky J**. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical? *N Engl J Med* 2004; **351**: 1445-1447 [PMID: 15459307 DOI: 10.1056/NEJMe048203]

149 **Lass-Flörl C**, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, Fille M. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. *Antimicrob Agents Chemother* 2008; **52**: 3637-3641 [PMID: 18694949 DOI: 10.1128/AAC.00662-08]

150 **Aoun M**, Klastersky J, Buvé K, Maertens J. Management of fungal infections in cancer patients: in Cancer Supportive Care: Advances in Therapeutic strategies. In: Lyman GH and Crawford J (eds). Informa Healthcare USA, New York, 2008: 89-114

151 **Sabatelli F**, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. *Antimicrob Agents Chemother* 2006; **50**: 2009-2015 [PMID: 16723559 DOI: 10.1128/AAC.00163-06]

152 **Walsh TJ**, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. *N Engl J Med* 1999; **340**: 764-771 [PMID: 10072411 DOI: 10.1056/NEJM199903113401004]

153 **Bochennek K**, Abolmaali N, Wittekindt B, Schwabe D, Klingebiel T, Lehrnbecher T. Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates. *Clin Microbiol Infect* 2006; **12**: 199-201 [PMID: 16451404 DOI: 10.1111/j.1469- 0691.2005.01316.x]

154 **Rassi SJ**, Melkane AE, Rizk HG, Dahoui HA. Sinonasal mucor­mycosis in immunocompromised pediatric patients. *J Pediatr Hematol Oncol* 2009; **31**: 907-910 [PMID: 19855305 DOI: 10.1097/MPH.0b013e3181bdbca0]

155 **Bow EJ**. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syn­dromes. *Semin Hematol* 2009; **46**: 259-268 [PMID: 19549578 DOI: 10.1053/j.seminhematol.2009.03.002]

156 **Akova M**, Paesmans M, Calandra T, Viscoli C. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. *Clin Infect Dis* 2005; **40**: 239-245 [PMID: 15655741 DOI: 10.1086/426815]

157 **Cornelissen JJ**, Rozenberg-Arska M, Dekker AW. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. *Clin Infect Dis* 1995; **21**: 1300-1302 [PMID: 8589161 DOI: 10.1093/clinids/21.5.1300]

158 **Spitzer TR**. Engraftment syndrome following hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2001; **27**: 893-898 [PMID: 11436099 DOI: 10.1038/sj.bmt.1703015]

159 **Crawford J**, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer* 2004; **100**: 228-237 [PMID: 14716755 DOI: 10.1002/cncr.11882]

160 **Lyman GH**. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. *J Natl Compr Canc Netw* 2005; **3**: 557-571 [PMID: 16038646]

161 **Lyman GH**, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. *Eur J Cancer* 1998; **34**: 1857-1864 [PMID: 10023306 DOI: 10.1016/S0959-8049(98)00222-6]

162 **Caggiano V**, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. *Cancer* 2005; **103**: 1916-1924 [PMID: 15751024 DOI: 10.1002/cncr.20983]

163 **Michels SL**, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH. Costs associated with febrile neutropenia in the US. *Pharmacoeconomics* 2012; **30**: 809-823 [PMID: 22804805 DOI: 10.2165/11592980-000000000-00000]

164 **Dulisse B**, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA. A retrospective study of the clinical and eco­nomic burden during hospitalizations among cancer patients with febrile neutropenia. *J Med Econ* 2013; **16**: 720-735 [PMID: 23452298 DOI: 10.3111/13696998.2013.782034]

165 **Liou SY**, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic burden of haematological adverse effects in cancer patients: a systematic review. *Clin Drug Investig* 2007; **27**: 381-396 [PMID: 17506589 DOI: 10.2165/00044011-200727060-00002]

166 **Wang XJ**, Lopez SE, Chan A. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a syste­matic review. *Crit Rev Oncol Hematol* 2015; **94**: 201-212 [PMID: 25600838 DOI: 10.1016/j.critrevonc.2014.12.011]

167 **Weycker D**, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. *Ann Oncol* 2008; **19**: 454-460 [PMID: 18083689 DOI: 10.1093/annonc/mdm525]

168 **Mayordomo JI**, Castellanos J, Pernas S, Ruiz-Borrego M, Velasco A, Frau A, Lamas MJ, Lara N, Gasquet JA, Sánchez J. Cost analysis of febrile neutropenia management of breast cancer patients in clinical practice in Spain. On behalf of the ENIA study group. *Ann Oncol* 2006; **17** Suppl 9: ix190-ix195, Ab 617P [DOI: 10.1093/annonc/mdl214]

169 **Durand-Zaleski I**, Vainchtock A, Bogillot O. L’utilisation de la base nationale PMSI pour déterminer le côut d’un symptôme: le cas de la neutropénie fébrile. *Journal d’ Economie Médicale* 2007; **25**: 269-280

170 **O’Brien C**, Fogarty E, Walsh C, Dempsey O, Barry M, Kennedy MJ, McCullagh L. The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting. *Eur J Cancer Care* (Engl) 2015; **24**: 125-132 [PMID: 24472035 DOI: 10.1111/ecc.12182]

171 **Hendricks AM**, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multi­center randomized trial. *J Clin Oncol* 2011; **29**: 3984-3989 [PMID: 21931037 DOI: 10.1200/JCO.2011.35.1247]

172 **Calhoun EA**, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. *Oncologist* 2001; **6**: 441-445 [PMID: 11675522 DOI: 10.1634/theoncologist.6-5-441]

173 **Pathak R**, Giri S, Aryal MR, Karmacharya P, Bhatt VR, Martin MG. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. *Support Care Cancer* 2015; **23**: 615-617 [PMID: 25556610 DOI: 10.1007/s00520-014-2553-0]

174 **Del Prete SA**, Ryan SP, Jacobson JS, Erichson RB, Weinstein PL, Grann VR. Safety and costs of treating neutropenic fever in an outpatient setting. *Conn Med* 1999; **63**: 713-717 [PMID: 10659471]

175 **Teuffel O**, Amir E, Alibhai S, Beyene J, Sung L. Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. *Br J Cancer* 2011; **104**: 1377-1383 [PMID: 21468048 DOI: 10.1038/bjc.2011.101]

176 **Pinto L**, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Com­parison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. *Curr Med Res Opin* 2007; **23**: 2283-2295 [PMID: 17697451 DOI: 10.1185/030079907X219599]

177 **Lyman GH**, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. *Clin Ther* 2009; **31**: 1092-1104 [PMID: 19539110 DOI: 10.1016/j.clinthera.2009.05.003]

178 **Fust K**, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. *Gynecol Oncol* 2014; **133**: 446-453 [PMID: 24657302 DOI: 10.1016/j.ygyno.2014.03.014]

179 **Somers L**, Malfait M, Danel A. PCN99 Cost-Utility of Granu­locyte-Colony Stimulating Factors For Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia in Breast Cancer Patients in Belgium. ISPOR 15th Annual European Congress and ISPOR 5th Asia-Pacific Conference. *Value in Health* 2012; **15**: A427 [DOI: 10.1016/j.jval.2012.08.2139]

180 **Hill G**, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC, Lyman GH. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses. *J Med Econ* 2014; **17**: 32-42 [PMID: 24028444 DOI: 10.3111/13696998.2013.844160]

181 **Crawford J**, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. *Ann Oncol* 2010; **21** Suppl 5: v248-v251 [PMID: 20555091 DOI: 10.1093/annonc/mdq195]

182 **National Comprehensive Cancer Network**. NCCN clinical practice guidelines in oncology (NCCN guidelines). Myeloid growth factors [Version2.2014]. Available from: URL: http://www.nccn.org/store/login/login. aspx?ReturnURL=http://www.nccn.org/professionals/physician\_gls/pdf/myeloid\_growth.pdf

183 **Ramsey SD**, McCune JS, Blough DK, McDermott CL, Clarke L, Malin JL, Sullivan SD. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. *Am J Manag Care* 2010; **16**: 678-686 [PMID: 20873955]

184 **Lyman GH**, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J. The impact of the granu­locyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. *Ann Oncol* 2013; **24**: 2475-2484 [PMID: 23788754 DOI: 10.1093/annonc/mdt226]

185 **Aarts MJ**, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. *J Clin Oncol* 2013; **31**: 4283-4289 [PMID: 24166522 DOI: 10.1200/JCO.2012.48.3644]

186 **Posner MR**, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM, Haddad RI. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med* 2007; **357**: 1705-1715 [PMID: 17960013 DOI: 10.1056/NEJMoa070956]

187 **Vermorken JB**, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med* 2007; **357**: 1695-1704 [PMID: 17960012 DOI: 10.1056/NEJMoa071028]

188 **Takenaka Y**, Cho H, Yamamoto M, Nakahara S, Yamamoto Y, Inohara H. Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. *Support Care Cancer* 2013; **21**: 2861-2868 [PMID: 23748486 DOI: 10.1007/s00520-013-1873-9]

189 **del Giglio A**, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. *BMC Cancer* 2008; **8**: 332 [PMID: 19014494 DOI: 10.1186/1471-2407-8-332]

190 **Welte K**. G-CSF: filgrastim, lenograstim and biosimilars. *Expert Opin Biol Ther* 2014; **14**: 983-993 [PMID: 24707817 DOI: 10.1517/14712598.2014.905537]

191 **Waller CF**, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A phase III randomized equivalence study of biosi­milar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. *Onkologie* 2010; **33**: 504-511 [PMID: 20926897 DOI: 10.1159/000319693]

192 **Gatzemeier U**, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. *J Thorac Oncol* 2009; **4**: 736-740 [PMID: 19404210 DOI: 10.1097/JTO.0b013e3181a52964]

193 **Aapro M**, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. *J Oncol Pharm Pract* 2012; **18**: 171-179 [PMID: 21610020 DOI: 10.1177/1078155211407367]

194 **Yancik R**. Cancer burden in the aged: an epidemiologic and demo­graphic overview. *Cancer* 1997; **80**: 1273-1283 [PMID: 9317180]

195 **Lewis JH**, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ. Participation of patients 65 years of age or older in cancer clinical trials. *J Clin Oncol* 2003; **21**: 1383-1389 [PMID: 12663731 DOI: 10.1200/JCO.2003.08.010]

196 **Kemeny MM**, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ. Barriers to clinical trial participation by older women with breast cancer. *J Clin Oncol* 2003; **21**: 2268-2275 [PMID: 12805325 DOI: 10.1200/JCO.2003.09.124]

197 **Dranitsaris G**, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. *Am J Clin Oncol* 2008; **31**: 369-374 [PMID: 18845996 DOI: 10.1097/COC.0b013e318165c01d]

198 **Balducci L**, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. *Oncologist* 2007; **12**: 1416-1424 [PMID: 18165618 DOI: 10.1634/theoncologist.12-12-1416]

199 **Timmer-Bonte JN**, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. *J Clin Oncol* 2005; **23**: 7974-7984 [PMID: 16258098 DOI: 10.1200/JCO.2004.00.7955]

200 **Hilpert F**, du Bois A, Greimel ER, Hedderich J, Krause G, Venhoff L, Loibl S, Pfisterer J. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged & gt; or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. *Ann Oncol* 2007; **18**: 282-287 [PMID: 17082513 DOI: 10.1093/annonc/mdl401]

201 **Hurria A**, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. *J Clin Oncol* 2011; **29**: 3457-3465 [PMID: 21810685 DOI: 10.1200/JCO.2011.34.7625]

202 **Extermann M**, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ, Balducci L. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. *Cancer* 2012; **118**: 3377-3386 [PMID: 22072065 DOI: 10.1002/cncr.26646]

Figure Legends

**D:\排版、组版\WJCIDv6i3\pmc-3\fig\WJCID-6-37-g001.tif**

**Figure 1 Algorithm to decide primary prophylactic granulocyte colony-stimulating factor usage.** Adapted from European Organization for Research and Treatment of Cancer Guidelines. Data taken from[13]. FN: Febrile neutropenia; G-CSF: Granulocyte colony-stimulating factor.

**D:\排版、组版\WJCIDv6i3\pmc-3\fig\WJCID-6-37-g002.tif**

**Figure 2 Relationship between the occurrence of febrile neutropenia and the severity of granulocytopenia.**

**D:\排版、组版\WJCIDv6i3\pmc-3\fig\WJCID-6-37-g003.tif**

**Figure 3 Decision tree for the administration of antibiotic therapy to low-risk patients with febrile nerutropenia.** N: Nausea; V: Vomiting; D: Diarrhea; *P. aeruginosa*: Pseudomonas aeruginosa.

**D:\排版、组版\WJCIDv6i3\pmc-3\fig\WJCID-6-37-g004.tif**

**Figure 4 Decision tree for administration of antibiotics to high-risk patients with febrile neutropenia.** ESKAPE: *E. coli*, *S. aureus*, *Klebsiella sp. Acinetobacter sp*, *P. aeruginosa*, *Enterococcus sp*; ESBL: Extended-spectrum β-lactamase; MRSA: Methicillin-resistant *S. aureus*; VRE: Vancomycin-resistant enterococci; HSCT: Hematopoietic stem cell transplant patients; *P. aeruginosa*: Pseudomonas aeruginosa.

Footnotes

Conflict-of-interest statement:None of the authors has any conflict of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Peer-review started:July 6, 2015

First decision:September 30, 2015

Article in press: June 3, 2016

**P- Reviewer**: Pavlovic M, Yoshida M **S- Editor**:Ji FF **L- Editor**: A **E- Editor**:Li D

**Table 1 Complications and death rates in patients with febrile neutropenia**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Complications (%)** | | **Mortality (%)** | |
|  | **Hemopathies** | **Solid tumors** | **Hemopathies** | **Solid tumors** |
| No bacteremia | 17 | 11 | 4 | 3 |
| Bacteremia | 30 | 35 | 9 | 13 |

Adapted from Klastersky *et al*[10].

**Table 2 Multinational Association for Supportive Care in Cancer scoring system**

|  |  |
| --- | --- |
| **Characteristic** | **Weight** |
| Burden of illness: No or mild symptoms | 5 |
| No hypotension | 5 |
| No chronic obstructive pulmonary disease | 4 |
| Solid tumor or no previous fungal infection | 4 |
| No dehydration | 3 |
| Burden of illness: Moderate symptoms | 3 |
| Outpatient status | 3 |
| Age < 60 yr | 2 |

Points attributed to the variable “burden of illness” are not cumulative. The maximum theoretical score is therefore 26.

**Table 3 Validation studies of Multinational Association for Supportive Care in Cancer score for predicting low-risk**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **N episodes** | **Patients with hema-tological malignancy (%)** | **Predicted at low-risk (%)** | **Se (%)** | **Sp (%)** | **PPV (%)** | **NPV (%)** |
| Klastersky *et al*[24], 2006 | 1003 | 55 | 72 | 79 | 56 | 88 | 40 |
| Stratum of hematological tumors | 549 | 100 | 70 | 77 | 51 | 84 | 40 |
| Stratum of solid tumor patients | 454 | 0 | 74 | 81 | 64 | 93 | 38 |
| Uys *et al*[22], 2004 | 80 | 30 | 73 | 95 | 95 | 98 | 86 |
| Cherif *et al*[23], 2006 | 279 | 100 | 38 | 59 | 87 | 85 | 64 |
| Klastersky *et al*[24], 2006 | 611 | 43 | 72 | 78 | 54 | 88 | 36 |
| Innes *et al*[25], 2008 | 100 | 6 | 90 | 92 | 40 | 97 | 20 |
| Baskaran *et al*[26], 2008 | 116 | 100 | 71 | 93 | 67 | 83 | 85 |
| Hui *et al*[27], 2011 | 227 | 20 | 70 | 81 | 60 | 86 | 52 |
| Carmona-Bayonas *et al*[28], 20111 | 169 | 0 | ? | 94 | 36 | NA | NA |

1Selected patients population (“apparently” stable patients). The characteristics were calculated for a test aiming to identify low-risk patients and may then differ from the original publications. Due to the case-control design of the study, the rate of patients predicted at low risk as well as the negative and positive predictive values are meaningless. Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value.

**Table 4 CISNE score**

|  |  |
| --- | --- |
| **Characteristic** | **Weight** |
| ECOG performance status ≥ 2 | 2 |
| Stress induced hyperglycemia | 2 |
| Chronic obstructive pulmonary disease | 1 |
| Chronic cardiovascular disease | 1 |
| Mucositis NCI grade ≥ 2 | 1 |
| Monocytes < 200/L | 1 |

ECOG: Electrocorticogram; NCI: National cancer institute.

**Table 5 Characteristics of CISNE score and Multinational Association for Supportive Care in Cancer score for predicting high-risk**

|  |  |  |
| --- | --- | --- |
|  | **CISNE** | **MASCC** |
| Predicting high risk, complications | 118 | 53 |
| Predicting low risk, no complications | 747 | 853 |
| Predicting high risk, no complications | 234 | 128 |
| Predicting low risk, complications | 34 | 99 |
|  | 1133 | 1133 |
| Se | 0.78 | 0.35 |
| Sp | 0.76 | 0.87 |
| PPV | 0.34 | 0.29 |
| NPV | 0.96 | 0.90 |
| Miscl rate | 0.24 | 0.20 |

High-risk of prediction: CISNE > 2, MASCC < 21. Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; MASCC: Multinational Association for Supportive Care in Cancer.

**Table 6 Major elements of the management of febrile neutropenia over time**

|  |  |
| --- | --- |
| 60’s | High mortality (> 90%) in FN with gram-negative bacilli bacteremia  Establishing the concept of empiric antibiotic therapy |
| 70’s | Anti-pseudomonal penicillins plus aminoglycoside combination as empiric therapy of choice  Oral non resorbable antimicrobials (aminoglycosides, glycopeptides, polymyxines, colimycin, in different combinations with nystatin), for intestinal flora suppression |
| 80’s | Establishing empirical antifungal therapy  Oral trimethoprim-sulfamethoxazole (or nalidixic acid and fluoroquinoles for prophylaxis in HM  Assessment of risk factors predicting complications: Talcott’s criteria |
| 90’s | Monotherapy supplanted combination  Ambulatory management first with IV antibiotics (ceftriaxone + aminoglycoside) and then with oral fluoroquinolones |
| 2000’s | Refinement of risk assessment: MASCC score  Risk-adapted therapy |

FN: Febrile neutropenia; HM: Hematologic malignancies; MASCC: Multinational Association for Supportive Care in Cancer.

**Table 7 Possible causes of fever in high risk neutropenic patients unresponsive to broad spectrum antimicrobials[139]**

|  |  |
| --- | --- |
| **Infectious causes** | **Frequency** |
| Fungal infections responding (40%)/resistant (5%) to empiric ATB | 45% |
| Bacterial Infections (cryptic foci, biofilm, resistant organism) | 10% |
| Toxoplasma gondii, mycobacteria, legionella, mycoplasma, chl.pneumoniae | 5% |
| Viral infections (HSV, CMV, EBV, HHV6, VZ, parainfluenza, RSV, influenza) | 5% |
| Graft *vs* host disease in hematopoietic stem cell transplantation | 10% |
| Undefined (drug, toxic effects of chemotherapy, antitumor response, undefined pathogens) | 25% |

HSV: Herpes simplex virus; CMV: Cytomegalovirus; EBV: Epstein-Barr virus; HHV6: Human herpesvirus 6; RSV: Respiratory syncytial virus.

**Table 8 Usual sensitivity and resistances of fungi against the different antifungals[149-151]**

|  |  |  |  |
| --- | --- | --- | --- |
| **Antifungal classes** | **Antifungal agent** | **Common resistances** | **Common sensitivity** |
| Polyenes | Amphotericine B: | Candida lusitaniae | Candida |
|  | Deoxycolate | Trichosporon | Aspergillus |
|  | Liposomal | Fusarium | Zygomycetes |
|  | Lipid complex | Scedosporium |  |
|  | Colloidal dispersion | Aspergillus terreus |  |
|  | 5 Fluorocytosine | Zygomycetes | Candida |
|  |  | Scedosporium | Torulopsis |
|  |  | Fusarium | T. glabrata |
|  |  | Cryptococcus | Cryptococcus |
|  |  | Candida | Phialophora |
|  |  |  | Cliadosporium |
|  |  |  | Exophiala |
| Triazoles | Fluconazoles | Aspergillus | Candida albicans and others |
|  |  | Candida kruzei | Candida glabrata1 |
|  |  | Candida glabrata | Cryptococcus neoformans |
|  |  | Zygomycetes | Blastomyces dermatitidis |
|  |  |  | Coccidioides |
|  |  |  | Histoplasma capsulatum |
|  | Itraconazole | Aspergillus niger | As itraconazole + Aspergillus flavus |
|  |  | Aspergilus terreus | Aspergillus fumigatus |
|  |  | Zygomycetes | Candida kruzei |
|  |  | Mucor | Trichophyton |
|  |  | Fusarium solani |  |
|  |  | Penicillium |  |
|  | Voriconazole | Zygomycetes | As itraconazole + Aspergillus niger |
|  |  | Sisyrinchium inflatum | Aspergillus tereus |
|  |  | Fusarium oxysporum, penicillium, Schedosporium apiospermum |  |
|  | Posaconazole | Trichosporon asahii | As voriconazole + Trichophyton |
|  |  |  | Zygomycetes |
| Echinocandins | Caspofungin | Cryptococcus |  |
|  | Micafungin | Zygomycetes |  |
|  | Anidulafungin | Fusarium |  |
|  |  | Paecilomyces lilacinus |  |
|  |  | Trichosporon |  |
|  |  | Schedosporium |  |
|  |  | prolificans |  |
|  |  | Schedosporium inflatum |  |
|  |  | Candida parapsilosis |  |

1Are not always sensible to the antifungals.